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ABSTRACT Patients with autoantibodies to the insulin receptor 
(Anti-R Ab) have severe insulin resistance and may exhibit either 
fasting hypoglycemia or hyperglycemia. Occasionally, both these 
phenomena are observed in the same patient at different times in their 
clinical course. In an effort to understand the factors that 
determine the patient's response to Anti-R Ab, we studied the effects 
of Anti-R Ab in vivo by the passive transfer of IgG to rats. 
IgG fractions from the plasma of Anti-R patients and control 
subjects were prepared by a four-step protocol consisting of: 1) 
ammonium sulfate precipitation, 2) insu1in-Sepharose affinity column, 
3) protein A-Sepharose affinity column, and 4) u1trafi1tration. 
Analysis of yield and purification of each of these steps was made. 
The ability of the Anti-R Ab to stimulate glucose oxidation and 
inhibit I< 1 25>-insu1in binding in vitro was determined. The antibody 
was able to stimulate glucose oxidation at a 100-fold lower 
concentration than was required to inhibit insulin binding. 
Anti-R Ab injected into fasting rats induced severe and 
persistent hypoglycemia (plasma glucose 15-30 mg/dl). Rats injected 
with control immunoglobulins maintained a plasma glucose within the 
range of 70 to 110 mg/dl (fasting). In comparison to the effects of 
insulin, the hyppglycemic response to Anti-R Ab had a slower onset 
(2-4 hr) and lasted longer (8-24 hr). In one animal, the persistence 
of the hypoglycemic effect of the antibody was observed after 72 
hours. Based on these in vivo and previous in vitro studies, we 
attribute the hypoglycemic response to an insulin-like effect of the 
Anti-R Ab . 
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I) INTRODUCTION 
A) HISTORY 
The first mention of a diabetes-1ike syndrome appeared in the 
papyrus of Ebers, the oldest medical text, dated by archaeologists at 
approximately 1500 B.C., in which a medical treatment for polyuria was 
described (1). In the second century A.D., the Greek physician 
Arateus first used the term "diabetes", and provided the first 
complete clinical description of this disease (1). In 1797, the 
English physician John Rollo was the first to propose dietary 
as treatment for the disease (1). Unfortunately, his 
dietary regimen was only occasionally followed by other physicians of 
his era. A century later, the Viennese physician Bernard Naunyn first 
proposed three separate categories of diabetes: juvenile, senile, and 
organic (1). This era of clinical observation, description, and 
empiric therapy of diabetes set the stage for the discovery of insulin 
and the introduction of modern pharmacologic therapy for 
hyperglycemia. 
In 1911, E.L. Scott first isolated insulin with the aid of an 
alcohol extraction procedure (2). However, because the published 
accounts of Scott's work were different from the findings in his 
thesis (2), the influential authority J.J.R. Macleod, in 1920, wrote 
that there was still no evidence for the pancreas' internal secretion. 
Working in Macleod's lab in 1922, the Canadian orthopedic surgeon 
Fredrick Banting, with the assistance of Charles Best, was the first 
to isolate a crude preparation of insulin and use it therapeutically 
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in a diabetic patient (3). Banting was awarded the Nobel Prize for 
this achievement in 1923. 
Despite a 3500 year descriptive history, the use of empiric 
non-pharmaco1ogica 1 therapy (diet) for almost two hundred years, and 
sixty years of pharmacologic therapy, the etiology and pathogenesis of 
diabetes mellitus, and many of the steps of insulin action, remain 
unknown to this day. It has been one of the most intensively 
investigated fields, yet the enigma remains. 
The huge corpus of medical research literature which developed 
following the isolation of insulin was limited mainly to examining the 
chemistry of insulin and insulin's metabolic effects. It was during 
this time that 
the breadth and diversity of insulin action began to be appreciated. 
Although Ehrlich and Langley had postulated the existence of cellular 
receptors at the turn of the century, research was dominated by a 
focus on insulin, largely because the hormone was readily available 
(4), the ability to measure blood glucose levels existed, and there 
were very strong correlations between insulin deficiency or excess and 
clinical findings. Thus, as Roth et a 1 (4) pointed out, for almost 
forty years the accepted dogma was that hyperglycemia was due to a 
deficency of insulin and hypoglycemia was due to insulin excess. This 
account was substantiated by the dramatic response of diabetes to 
insulin and the similarity of patients with islet cell tumors to 
diabetics who had received too much insulin. In sum, the field of 
endocrinology was limited to the study of hormones and their metabolic 
effects, and did not encompass the mechanism of insulin action at the 
peripheral level. 
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B) CLASSIFICATION OF DIABETES 
The existence of different types of diabetes had been clinically 
suspected since Naunyn's time (1). Diabetics have been traditionally 
classified as either juvenile-onset or maturity-onset diabetics. 
However, this classification system, based on chronological age, had 
definite shortcomings, and the ambiguities in classification were 
apparent by the multitude of descriptive names which evolved: 
juvenile diabetes, juvenile-onset type diabetes, ketosis prone 
diabetes, brittle diabetes, adult-onset diabetes, maturity-onset type 
diabetes, ketosis resistant diabetes, stable diabetes, asymptomatic 
diabetes, chemical diabetes, borderline diabetes, and latent diabetes. 
Forty-five years ago, Himsworth and Kerr (5) had proposed 
differentiating diabetics into two classes on the basis of the 
response of their plasma glucose level to an oral glucose - 
intravenous insulin challenge. This approach was not widely accepted 
and even less widely practiced. However, in retrospect, the reasons 
are unclear, since this division certainly did not challenge either 
clinical descriptions or published data at the time (6). 
With the conceptual advance of the principle of competitive 
binding formulated by Berson and Yalow (7), and the concomitant 
development and use of the radioimmunoassay in determining plasma 
insulin levels, two main findings became apparent. First, there 
definitely did exist a population of diabetics with an absolute 
insulin deficiency. Clearly, these patients supported the earlier 
formulation of hyperglycemia solely as a result of insulin deficiency. 
This group included juvenile-onset, juvenile-onset type, 
ketosis-prone, and brittle diabetics. Secondly, it was obvious that a 
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majority of diabetics did not fit the earlier concept of insulin 
deficiency, and despite normal or near-normal levels of plasma 
insulin, these patients had persistent hyperglycemia. As Berson and 
Yalow pointed out, "the tissues of the maturity-onset diabetic do not 
respond to his insulin" (7). While these patients had a 'relative' 
decrease in plasma insulin level considering their hyperglycemia, they 
also had a resistance to insulin at the tissue level. These findings 
had two major ramifications. First, they have necessitated a revision 
of diabetes nomenclature, diagnostic criteria, and classification 
scheme for diabetic patients (8). Secondly, they fostered the 
development of the concept of insulin resistance and the evolution of 
the field of endocrinology to include pathophysiology at the target 
cell level. 
The overall prevalence of diabetes mellitus is estimated to be 
two percent of the general population (8). This estimation is based 
on a number of population studies, but it must be recognized that 
there exists considerable difficulty in attempting to estimate the 
prevalence of a disease with such a broad spectrum of clinical 
manifestations. Of the total population of diabetics (see Table I), 
approximately ten to twenty percent are afflicted with Type I, 
insulin-dependent diabetes mellitus (IDDM) (9). These patients 
usually have an abrupt onset of symptoms, insu1inopenia , and 
dependence on injected insulin to sustain life, and are prone to 
ketosis. This classification includes the former groups of 
juveni1e-onset, ketosis-prone , and brittle diabetes. Although this 
commonly presents at a young age, it can occur at any age (9). IDDM 
appears to have a heterogeneous etiology, with both genetic and 
environmental factors contributing as possible precipitants of this 
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disease (10). Further, there seems to be a correlation with the 
presence of antibodies directed against pancreatic islet cells, with 
eighty-five percent of newly diagnosed patients found to have the 
antibody within the first year of illness (10). 
In contrast, the majority (80%) of hyperglycemic patients are 
afflicted with Type II, non-insulin dependent diabetes (NIDDM). These 
patients are not dependent on insulin for the prevention of ketonuria 
and are not prone to ketosis. They typically have normal, or 
near-normal, levels of insulin associated with insulin resistance (8). 
They may require insulin for correction of symptomatic, or persistent, 
fasting hyperglycemia if control can not be achieved with diet, 
exercise, and/or oral hypoglycemic agents. These patients may be 
asymptomatic for years. This classification group includes the former 
groups of maturity-onset, adult-onset, ketosis-resistant and stable 
diabetes (9). Although it typically is manifested in patients over 
forty years of age, it may also afflict children, so again, age is not 
a valid diagnostic criterion. NIDDM has been subdivided on the basis 
of the presence or absense of obesity. Sixty to ninety percent of all 
NIDDM patients are obese (9), and therefore obese patients constitute 
the majority of all diabetic patients. However, it must be remembered 
that the converse is not true, i.e. most obese people are not 
diabetic. 
There is a third subclass of diabetes (see Table I - "Other 
Types") formerly called secondary diabetes. This group includes 
diabetes arising as a consequence of a primary pancreatic disease, 
other primary endocrine disturbance (acromegaly, Cushing's syndrome, 
pheochromocytoma, glucagonoma, somatostatinoma, or primary 
aldosteronism), drug or chemical-induced diabetes, diabetes secondary 
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to insulin receptor abnormalities, and diabetes associated with 
genetic anomalies. 
Although a description of diagnostic criteria is beyond the scope 
of this paper, the establishment of these international standards of 
classification (9) has greatly facilitated basic research, clinical 
research, and treatment of diabetic patients. 

H3LE I - Classification of Diabetes Mellitus - from (9) 10 
LASS FORMER TERMINOLOGY ASSOCIATED FACTORS 
nsulin-dependent type Juvenile diabetes, juvenile- Evidence regarding etiology 
I DOM), Tyne I onset diabetes, juvenile- suggests genetic and en- 
onset-type diabetes, JOD, vironmental or acquired 
ketosis-prone diabetes, factors, association with 
brittle diabetes certain HLA types, and 
abnormal immune responses 
including autoimmune 
reactions 
I 
loninsulin-dependent 
types (Ninnri), 
Tyne 11 
1. Nonobese NIDDM 
2. Obese NIDDM 
Other types, including 
diabetes associated 
certain conditions 
and syndromes: 
1. Pancreatic disease 
2. Hormonal 
3. Drug or chemical induced 
4.Insulin receptor 
abnormalities 
5.Certain genetic 
syndromes 
6.Other types 
Adult-onset diabetes, 
maturity-onset diabetes, 
maturi t.y-onset-type 
diabetes, MOD, ketosis- 
resistant diabetes, 
stable diabetes 
Secondary diabetes 
There are probably multiple 
etiologies for this class, 
the common outcome being 
derangement of carbohydrate 
metabolism. Evidence on 
familial aggregation of 
diabetes implies genetic 
factors, and this class 
includes diabetes 
presenting in children and 
adults in which autosomal 
dominant inheritance has 
been clearly established 
(formerly MODY type, 
maturity-onset diabetes 
in the young). Environmental 
factors superimposed on 
genetic susceptibility are 
probably involved in the 
onset of the NIDDM types. 
Obesity is suspected as an 
etiologic factor and is 
recommended as a criteria 
for dividing NIDDM into two 
Sllhrl a ssps . arrnrdi no tn thp 
presence or absence of 
obesity. 
This subclass contains a 
variety of types of 
diabetes, in some of which 
the etiologic relationship 
is known (e.g. diabetes 
secondary to pancreatic 
disease, endocrine disease, 
or the administration of 
certain drugs). In others, 
an etiologic relationship 
is suspected because of 
a higher frequency of 
association of diabetes 
with a syndrome or 
condition (e.g. a number 
of genetic syndromes). 
CLINICAL CHARACTERISTICS 
Persons in this subclass are 
dependent on injected 
insulin to prevent ketosis 
and to preserve life, 
although there may be 
pre-ketotic, non-insulin- 
dependent phases in the 
natural history of the dis¬ 
ease. In the preponderance 
of cases, onset is in 
youth, but IDDM may occur 
at any age. Characterized 
by insulinopenia. Islet cell 
antibodies are frequently 
present at diagnosis in 
this type. 
Persons in this subclass are 
not insulin-dependent or 
ketosis-prone, although they 
may use insulin for 
correction of symptomatic 
or persistent hyperglycemia 
and they can develop ketosis 
under special circumstances, 
such as episodes of infection 
or stress. Serum insulin levels 
may be normal, elevated, or 
depressed. In the preponderance 
of cases, onset is after 
aqe 40, but NIDDM is known to 
occur at all ages. About 
60-90% of NIDDM subjects 
are obese and constitute a 
subtype of NIDDM; in these 
patients, glucose tolerance 
is often improved by weight 
loss. Hyperinsulinemia and 
insulin resistance characterize 
some patients in this subtype. 
In addition to the presence 
of the specific condition 
or syndrome, diabetes 
mellitus is also present. 
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C) INSULIN RESISTANCE 
In clinical practice, insulin resistance is usually accompanied 
by elevations of endogenous plasma insulin and a decreased effect of 
exogenously administered insulin (11). Therefore, while at the 
clinical level, insulin resistance is not a major clinical problem, it 
is a silent concomitant to many clinical disorders (12). As stated by 
Kahn (13), "insulin resistance may be said to exist whenever normal 
concentrations of hormone produce a less than normal biologic 
response". 
In a recent article, Reaven (14) described the difficulties in 
characterizing insulin resistance in vivo , and described the 
strengths and weaknesses of a number of techniques used to study this 
"resistance", including: the insulin tolerance test, oral 
glucose-intravenous insulin tolerance test, insulin suppression test, 
the hyperglycemic insulin clamp, and the euglycemic insulin clamp. 
While he pointed out that all of these techniques are limited, he 
concluded that they all invariably support the idea that insulin 
resistance (both hepatic and peripheral) is a major component of 
NIDDM. Defronzo stated that tissue sensitivity is more commonly 
impaired in NIDDM than is beta-cell function (15). In NIDDM patients 
with fasting hyperglycemia, insulin secretion (relative to the blood 
glucose levels) was also characteristically, but not invariably, 
diminished (15). Insulin resistance is established as a major 
component in most, if not all, NIDDM patients. Furthermore, the more 
severe the diabetes, the greater the magnitude of insulin resistance 
(16). A number of other disorders in which insulin resistance occurs 
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are listed in Table II. In one study which used the euglycemic 
insulin clamp technique, significant insulin resistance has even been 
implicated as a contributing factor in IDDM (17), although this 
finding has been recently challenged (18). 
Through the use of in vitro studies, it has been possible to 
explore the concept of insulin resistance at the cellular level. 
Changes which cause an alteration of insulin resistance can occur at 
three levels: pre-receptor, receptor-ce11 surface, and post-receptor 
(13). Pre-receptor insulin resistance is caused by factors which 
reduce free-insulin concentration, such as increased insulin 
degradation, which may occur in pregnancy (19), or binding to other 
serum proteins, e.g. anti-insulin antibodies. Although anti-insulin 
antibodies commonly occur in patients treated with exogenous insulin, 
they rarely are of clinical importance (20). At the receptor-ce11 
surface level, a decrease in the insulin receptor's affinity for 
insulin or in the concentration of the receptor itself can cause 
insulin resistance. Finally, a decrease in the ability of the 
receptor to bring about the terminal actions, or biologic effects, of 
insulin action would lead to insulin resistance. 
At the cellular level, it has also been possible to separate 
insulin resistance into two components, either or both of which may 
contribute to the final picture of insulin resistance (13). Insulin 
insensitivity is said to occur when it is still possible to elicit the 
same maximal biological response from a cell, although it may require 
a higher than normal insulin concentration. Usually sensitivity is 
characterized by the insulin concentration which is required for 
half-maximal stimulation of a biological effect. Therefore, decreased 
sensitivity is characterized by a shift in the "dose-response curve" 
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to the right. In contrast, decreased insulin responsiveness occurs 
when it is no longer possible to elicit the same maximal biologic 
effect, regardless of the concentration of insulin used. 
Insulin resistance as a result of pre-receptor changes is 
typically manifested as decreased sensitivity, whereas changes at the 
post-receptor level characteristically decrease the insulin 
responsiveness (13). An alteration at the insulin receptor-ce11 
surface level may produce altered sensitivity and/or responsiveness, 
although most frequently changes in receptor affinity, as well as 
changes in receptor number, cause decreased sensitivity (13). 
The recognition of the role of insulin resistance in a large 
variety of disease states, and the recognition that pathophysiology 
occurs at the target cell level, has led to an expansion of the focus 
of the field of endocrinology. The immediate importance of 
understanding ligand-receptor interactions in the normal physiology of 
insulin action, and its pathological derivatives, has triggered an 
intense research effort. A tremendous amount of biochemical and 
morphological information has been generated about the interaction of 
insulin with its receptor. Before addressing the focus of this study, 
and in order to appreciate the complexity of the insulin endocrine 
system, a review of these recent findings in the biology of insulin is 
mandatory. One of the most important findings to be derived from 
these studies has been that the insulin receptor and the target cell 
are not static entities, but are incredibly dynamic, with alterations 
in receptor affinity and receptor concentration occurring constantly 
(21,22). 
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Table II - Clinical States of Insulin Resistance - from (11) 
MAJOR 
Diabetes mellitus, Type II 
Obesity 
Insulin Antibodies 
Cushing's syndrome 
Acromegaly 
Pregnancy 
Ketoacidosis (?) 
MINOR. (PARTIAL LIST) 
Lipoatrophic diabetes 
Ataxia telangiectasia 
Prader-Willi syndrome 
Syndromes of acanthosis nigricans and insulin resistance 
Werner syndrome 
Leukemia 
Collagen vascular diseases 
Sepsis 
Burns 
Uremia 
Liver disease 
Cirrhosis 
Hepatitis 
Hemochromatosis 
Injury 
Huntington disease 
Pertussis infection and vaccination 
Leprechaunism 
A1strom syndrome 
Myotonic dystrophy 
Laurence-Moon syndrome 

D) INSULIN-INSULIN RECEPTOR INTERACTION 
As noted previously, the abundance of research generated 
following the isolation of insulin was limited to examining metabolic 
effects of insulin action. With the advent of the radioimmunoassay, 
it became possible to accurately determine plasma insulin levels, and 
thereby to recognize the existence of variability in hormone action at 
the peripheral cellular level. Recent advances in the understanding 
of insu1in-receptor interactions have occurred largely as a result of 
technical advances made in the past fifteen years, which enable 
investigators to dissect out and examine discrete steps in insulin 
action. These technical advances include the development of methods 
for labeling hormone with high specific radioactivity while 
maintaining biologic activity (23,24), the development of monomeric 
ferritin-insu1in complexes (25), and the recent development of 
photoaffinity probes which can covalently bind to the insulin receptor 

16 
With the aid of these techniques for labeling the insulin molecule 
and the insulin receptor, an astonishing amount of new information has 
been gathered. In order to systematically present this data in a 
coherent manner, I have arbitrarily categorized it into six different 
areas, corresponding to the sequence of events leading from 
circulating insulin to its effects on intracellular metabolism. These 
divisions are: 
1) insulin and insulin recptor structure 
2) binding of insulin to its receptor 
3) transformation of insulin-receptor interaction into a 
transmembrane signal 
4) generation of an intracellular message (or messengers) 
5) subsequent chemical modification of appropriate enzymes 
and transport systems which result in biochemical 
effects 
6) insu1in-insulin receptor signal termination 
As this is a rapidly evolving field of research, it will become 
apparent in the following discussion that our understanding of each of 
these areas varies greatly, and that within each area, the 
interpretation of experimental findings is often controversial. 

1) Insulin and Insulin Receptor Structure 
Through the use of protein sequencing and X-ray diffraction 
analysis, the structure of insulin has been known for more than a 
decade (28,29,30). It is a protein with a molecular weight of 5600 
daltons (31). It is synthesized as a single polypeptide chain, but is 
cleaved into two separate chains (A and B) linked by two disulfide 
bonds. Its binding site is believed to consist of amino acid residues 
12, 16, and 21 through 26 of the B chain and 1, 4, 19, and 21 of the A 
chain (31). 
In contrast to insulin, our understanding of the insulin receptor 
molecule is meager and has only developed within the past five years. 
It is an integral, membrane-bound glycoprotein, located solely within 
the outer leaflet of the plasma membrane (32). A recent model by 
Czech and Massague (33) for the minimum subunit composition of the 
insulin receptor, based on affinity labelling techniques, proposes a 
symmetrical disulfide linked heterotetramer consisting of two alpha 
chains (M.W. 125,000 daltons) and two beta chains (M.W. 90,000 
daltons). These glycoprotein subunits are arranged in the 
configuration (beta-S-S-a 1pha)-S-S-(a1pha-S-S-beta). This molecular 
model has a striking similarity to the immunoglobulin molecule, at 
least in the manner in which its subunits are aggregated (33). The 
disulfide bond linking the two alpha-S-S-beta halves (class I 
disulfide) appears to be more sensitive to reducing agents than those 
linking the alpha and beta subunits (class II disulfides). When the 
class I disulfide is reduced, the receptor retains its ability to bind 
insulin and to initiate a biological response. This model is 
virtually identical to the model proposed by Jacobs and Cuatrecasas 
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(34), who used a totally different isolation technique, affinity 
chromatography, to isolate the receptor. The concurrence of these two 
separate methods is further support for the current concepts. 
The alpha subunit appears to contain, or be nearer to, the 
insulin binding site and is preferentially labelled by photoaffinity 
labelling techniques (27,35). In addition, it is possible that the 
beta subunit may act as the effector limb of the receptor and undergo 
phosphorylation upon insulin binding (36). 
It is important to realize that this structural model is for the 
minimum subunit composition of the binding component of the insulin 
receptor. Recent evidence from radiation inactivation studies (37) 
suggest that there may be a separate affinity regulatory component of 
the insulin receptor similar to the GTP binding site in adenylate 
cyclase systems (38). 
2) Insulin Binding 
The initial step in insulin action is binding to an insulin 
receptor molecule on the plasma membrane of the cell (39). This 
interaction is critical to insulin action, and without this specific 
binding, the circulating hormone is impotent (40). This interaction 
mediates all of the rapid, short-term effects of insulin on the 
cellular metabolism of carbohydrates, lipids, proteins, and perhaps 
all of the cellular effects observed at physiologic concentrations of 
insulin (11). Furthermore, the cell surface - the interface between 
the cell and the "internal millieu" - is one of the major sites of 
modulation of the peripheral sensitivity to insulin action (41). 
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The three main determinants of insulin binding are the ambient 
insulin concentration, the receptor concentration, and the receptor 
affinity for binding insulin. The ambient insulin concentration is a 
balanced equilibrium between beta cell secretion and plasma clearance. 
The other two determinants of insulin binding are controlled at the 
target cell level and are the key factors in modulating peripheral 
sensitivity at the cell surface, and are therefore major determinants 
of peripheral sensitivity and resistance. 
The method used in assessing hormone binding is called the 
radioreceptor assay and is based on the classic radioimmunoassay. 
Typically, a small amount of "tracer" I< 125>-labeled insulin and a 
wide range of concentrations of unlabeled insulin are allowed to 
compete for binding sites under steady-state conditions, standardized 
with respect to time, temperature, pH, ionic strength, etc. (42). The 
receptor-bound and free hormone can then be separated and the 
radioactivity counted. The data is analyzed in three formats: 
competition-inhibition curve, Scatchard plot, and the affinity profile 
(see Figure 1). Provided that the "tracer" insulin behaves like the 
unlabelled insulin, analysis of the data reveals the affinity (Keq) of 
the interaction between insulin and its receptor binding site, and an 
estimate of the number of receptors per cell. In the commonly used 
Scatchard analysis (43), the slope of the plot is the binding affinity 
and the intercept on the abcissa is the number of receptors per cell. 
Therefore, Scatchard analysis of the competitive binding studies 
allows characterization of the two main determinants of insulin 
sensitivity at the cell surface. 
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Figure 1 - Analysis of Insulin Competitive Binding Studies: 
A) Competition-Inhibition Curve, B) Scatchard 
Plot, C) Affinity Profile . ( Shaded areas 
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The hallmark of insulin-insulin receptor binding is specificity 
(39). A major function of the receptor molecule is recognition and 
21 
discrimination. The receptor must be able to recognize and bind, with 
sufficiently high affinity, a molecule circulating at extremely low 
concentrations on the order of nanomoles. Furthermore, the receptor 
must be able to discriminate between the insulin molecule and the 
millions of other molecules that the cell is exposed to at the same 
time (12). This specificity is the most important defining 
characteristic of the receptor and the property which differentiates 
functional binding to a physiologic receptor from non-specific binding 
to an inorganic substance like talc (44). 
In practice, binding specificity is demonstrated by the 
competitive binding inhibition of radioactive1y labelled hormone by 
unlabelled substances related in some way to the hormone. More 
specifically, this quality is assessed by showing that the relative 
ability of insulin analogs to compete for binding sites is in direct 
proportion to their binding affinity and their biologic activity (31). 
As Ginsberg illustrated, avian insulin, porcine insulin, porcine 
proinsulin, and desalanine-desaparagine insulin bind with decreasing 
which match their relative biologic potencies(31). molar 
Freychet et a 1 ( 23,45) and Glieman et a 1 (46) have examined over forty 
insulin analogs, and in every case they have shown that there exists a 
close correlation between binding affinity and biologic activity. For 
most polypeptide hormones, the differences in biologic activity can be 
determined solely by differences in binding affinity for the hormone 
receptor. Indeed, this property has been exploited to measure hormone 
concentrations through the use of the radioreceptor assay (47). 
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Using the competitive binding techniques described above, it has 
been shown that insulin binding is rapid and reversible (39). It is 
influenced by time of exposure, temperature, ionic environment, and pH 
- with an optimum between pH 7.8 and 8.0 (31). The binding process 
does not require energy (48). It is important to recognize that while 
these findings are important for characterizing the chemical 
interaction between insulin and its receptor, they are seldom subject 
to variance in vivo . 
A model for the interaction of insulin with its receptor, based 
on a simple bimolecular reaction, is presented below: 
K 3 . 
<H> + <R> . <HR> 
where Ka/Kd = <HR>/<H> <R> = Keq 
and biological response = f <HR> 
In this model, <H> is the ambient concentration of insulin, <R> is the 
concentration of unoccupied insulin receptors, <HR> is the 
concentration of insulin-receptor complexes, Ka and Kd are the 
association and dissociation rate constants, respectively, Keq is the 
the affinity constant for insulin binding, and the net biological 
response is some function (f) of the concentration of insulin-receptor 
complexes (39). Therefore, the concentration of insulin-receptor 
complexes determines the magnitude of the signal to the cell and is a 
major determinant of the magnitude of the cellular response to 
circulating insulin (39). 
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Both membrane and intracellular biologic actions of insulin are 
believed to be linked in some way to the insulin-receptor complex 
(39). In addition, the insulin-receptor complex may: 1) regulate the 
degradation of insulin, 2) regulate degradation of the receptor, 3) 
regulate receptor concentration, 4) regulate receptor affininty, and 
5) cross-link and translocate the insulin-receptor complex (4). These 
possibilities will be discussed in subsequent sections. 
While the simple bimolecular model may be appropriate for other 
hormone-receptor interactions (e.g. calcitonin (49) or prolactin 
(50)), the model is definitely too simplistic for the interaction of 
insulin, at physiologic concentrations, with its receptor (51). 
Insulin binding influences both the affinity of the receptor for 
insulin and the concentration of the receptor itself. The simple 
bimolecular model cannot account for these observations. With these 
limitations understood, the bimolecular model can be used only as a 
framework upon which to build a better understanding of the 
complexities of insu1in-insu1in receptor binding. 
Because receptor affinity and receptor concentration are the 
major cellular determinants of insulin binding, and thereby major 
determinants of peripheral insulin sensitivity, these parameters have 
been studied in depth in the past decade. Their relevance to the 
phenomenon of insulin resistance necessitates a review of recent 
advances in our understanding of these parameters. In general, 
changes in receptor affinity occur in response to acute metabolic 
changes (e.g. fasting) whereas changes in receptor concentration 
develop in response to more chronic conditions over periods of weeks 
to months (11). 

2 a) Insulin Binding: Receptor Affinity 
Scatchard analysis of insulin binding reveals a plot which is 
concave upwards. Two distinct models have been proposed to account 
for this finding. The first proposes the existence of two separate 
classes of insulin receptors: a relatively small number of high 
affinity sites and a large number of low affinity binding sites (52). 
The second model, advanced by De Meyts et a 1 (53), proposes that 
site-site interactions occur which induce a negative cooperativity , 
i.e. increased receptor site occupancy is accompanied by progressively 
decreased binding affinity. 
Although this is still a controversial issue, the concept of 
negative cooperativity is generally accepted. Kinetic analysis of 
insulin binding has shown that the initial dissociation rate of 
labeled hormone from the receptor is increased when a large 
concentration of unlabeled hormone is added to a known concentration 
of hormone bound to cells. Further, it seemed that it didn't matter 
whether the unlabeled hormone was added in the association or 
dissociation phase (53). These findings support the negative 
cooperativity model. This kinetic analysis is important because it is 
impossible to distinguish between negative cooperativity and binding 
site heterogeneity on the basis of a steady-state analysis (54). At 
present, negative cooperativity seems to account for experimental 
findings better. Teleologically, the negative cooperativity provides 
a mechanism for exquisite sensitivity to low levels of hormone and 
allows a "buffering" mechanism against acute elevations in ambient 
levels of hormone (53). 
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This cooperativity phenomenon has been investigated further with 
the use of insulin analogs (31). Insulin analogs induce negative 
cooperativity in proportion to their binding affinity and bioactivity. 
but do not dimerize in solution (55). binding 
Therefore, it seems insu1in-insu1in interactions are not important in 
the mechanism of negative cooperativity. Using desoctapeptide and 
desa1anine-desapargine insulin, it was found that these insulin 
derivatives do not induce negative cooperativity even when they 
completely occupy the receptor (31). On this basis it was proposed 
that insulin binding to its receptor involves a bioactive site and a 
separate cooperative site (residues 23 - 26 and perhaps 27 - 29 of the 
B-chain and 21 of the A chain) (31,56). 
Insulin receptor affinity can also be altered by pH (57), ionic 
environment (12), and temperature (12). However, on the basis of the 
above information, it appears that ambient insulin concentration is a 
major factor affecting insulin receptor affinity (31,58). 
2 b) Insulin Binding; Receptor Concentration 
The insulin receptor accounts for approximately one-tenth of a 
percent of total membrane bound proteins (48). Estimates of the 
actual numbers of receptors on different cell types vary between one 
hundred on the erythrocyte (59) to three hundred thousand on the 
adipocyte (60). However, these figures are presented mainly to 
provide a perspective. The amount of cell surface insulin receptors 
is never fixed, but is determined by a balance of synthesis, 
degradation and possibly recycling. Furthermore, the concentration of 
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cell surface receptors is subject to physiologic regulation. This 
regulation can result in alterations in the cellular sensitivity to 
insulin (61). 
"Down-regulation" of the Insulin Receptor 
Data generated from a variety of animal and human studies and in 
a variety of tissues have shown inverse correlations between ambient 
insulin concentration and the concentration of the insulin receptor. 
In the ob/ob mouse with genetic obesity, hyperglycemia, 
hyperinsu1inemia, and endogenous and exogenous insulin resistance, 
Kahn et a 1 ( 56,62) have shown that the decrease in insulin binding in 
these animals was due solely to a decrease in the number of insulin 
receptors. The decreased receptor concentration was related to the 
chronic hyperinsulinemia. In obese human patients, both diabetic and 
those with normal glucose tolerance, decreased insulin receptor 
concentration has been demonstrated in adipocytes (31,63) and 
peripheral mononuclear cells (63,64,65). Further, the reduction in 
the number of receptors per cell correlated well with the level of 
circulating insulin (64). This reduction of insulin receptor 
concentration in obesity was also reversible, as receptor 
concentration returned to normal as insulin levels decreased (41). 
In 1974, Gavin et a1 (66) demonstrated in vitro that incubation 
of cultured human lymphocytes with high concentrations of insulin led 
to a time and concentration dependent decrease in receptor number. 
After incubation with 10<-8>M insulin, there was a forty percent loss 
of receptors. With 10<-6>M insulin, a seventy percent loss of 
receptors occurred within four hours. This receptor loss, or 
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"down-regulation", was specific for the hormone-receptor system being 
manipulated, e.g. down-regulation of the growth hormone receptor has 
no effect on the insulin receptor (67). Insulin analogs cause 
down-regulation in direct proportion to their bioactivity, 
demonstrating the specificity of the phenomenon (48). Down-regulation 
does not seem to require binding site - binding site interactions, 
since insulin analogs which do not cause negative cooperativity will 
initiate down-regulation (31). Therefore, it appears that 
down-regulation is a receptor mediated process triggered through the 
bioactivity site of the receptor molecule. Insulin receptor 
concentration is inversely related to ambient insulin concentration 
(39,68). This down-regulation is a fundamental mechanism for the 
regulation of target cell sensitivity (69). 
At the molecular level, using the techniques of radioactive 
pulse-chase labeling with S<35>-methionine and surface labeling with 
Nal<125> and lactoperoxidase in cultured human lymphocytes, Kasuga e_t 
al (70) have shown that insulin exerts its down-regu1atory effect by 
increasing the degradation rate, and thereby increasing the turnover 
rate of the receptor. Insulin had no effect on synthesis. Using a 
heavy isotope density shift technique in cultured 3T3-L1 adipocytes, 
Lane e t a1 (71) obtained similar findings. Ronnet e t a 1 (72), also 
using 3T3-L1 adipocytes, demonstrated that approximately one and a 
half hours is required for synthesis of the receptor molecule and 
another one and a half hours required for insertion into the plasma 
membrane. Down-regulation had no effect on the time required (3 
hours) for newly synthesized receptors to reach the cell surface. 
Therefore, it appears that insulin mediates its effect on receptor 
concentration in down-regulation solely via an alteration in the rate 
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of receptor degradation, without altering the rate of receptor 
synthesis. 
Insu1in-Insu1in Receptor "Internalization" 
The mechanisms by which insulin influences its receptor 
concentration and increases the degradative rate have been the focus 
of a great many biochemical and morphologic studies in the past five 
years. A major finding is that insulin and its receptor are 
"internalized" within the cell following the initial binding 
interaction . 
In isolated hepatocytes, following the initial binding of 
I<125>-insulin to the cell surface, this "tracer" insulin was 
progressively internalized in a time and temperature dependent fashion 
(73). At apparent steady state, approximately sixty percent of the 
I<125>-insu1in was found on the plasma membrane and approximately 
forty percent was found in the cell's interior. In isolated rat 
adipocytes, internalization of both monomeric ferritin-labelled 
insulin (74,75), and I<125>-insu1in (76,77) were demonstrated. In the 
3T3-L1 adipocyte, internalization of I<125>-insu1in was demonstrated 
(78). In the cultured human lymphocyte, internalization of 
I<125>-insulin occurred, but to a much lesser extent than in these 
other cell types (79). These studies show unequivocally that insulin 
enters the target cell. 
The recent development of covalent photoaffinity labeling 
techniques has allowed direct demonstration that the insulin receptor 
is also internalized along with the insulin molecule in isolated rat 
adipocytes (80,81,82), hepatocytes (83,84,85,86), and 3T3-L1 
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adipocytes (27). By the use of cell solubilization and time-course 
studies in the insu1in-induced down-regulation of isolated adipocytes, 
Olefsky (80) has shown that the appearance of intracellular receptors 
corresponded with the disappearance of receptors from the cell 
surface. The internalized receptors demonstrated the same specificity 
for insulin anologs and the same reactivity with anti-insulin receptor 
antibodies. Olefsky concluded that incubation of cells with insulin 
caused a down-regulation characterized by translocation of receptors 
from the cell surface to an intracellular compartment. In contrast, 
using photoaffinity probes (80), it was not possible to demonstrate 
internalization of the insulin receptor in IM-9 cultured human 
lymphocytes. Of note, despite intensive investigations with this cell 
line, no post-receptor effect has been demonstrated (87). 
In most cell types studied, internalization of both insulin and 
its receptor occur. Evidence suggests that the internalization occurs 
via receptor-mediated endocytosis (51,81). Endocytosis occurs via 
invagination of a segment of the plasma membrane which then fuses and 
pinches off from the plasma membrane. Conditions known to inhibit 
endocytosis, such as low temperature and depletion of metabolic 
energy, are associated with a decrease in insulin internalizaion and 
insu1in-induced receptor loss (69). Insulin and its receptor are 
therefore internalized within a vesicle. These vesicles then become 
associated with progressively larger membrane-bound structures (78). 
With 3T3-L1 adipocytes, endocytosis of ferritin and its progressive 
association with intracellular membrane-bound structures exactly 
parallelled the receptor-mediated endocytosis of insulin (84). This 
suggests that the specificity of the process is dictated by the 
receptor (84) and not the hormone. The rate controlling steps of the 
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process are unclear, but since internalization is proportional to the 
concentration of insulin bound to the plasma membrane, it has been 
proposed that binding itself may be the controlling step in 
internalization (88). The actual rate of internalization is rapid, 
with the process completed within minutes of binding (58,75,81). 
Therefore, receptor-mediated endocytosis of insulin is rapid and is 
time, temperature, and energy dependent (51). 
While most investigators concur that internalization of the 
insulin-receptor complex occurs through receptor-mediated endocytosis 
into a small vesicle which progressively associates with larger 
membrane bound structures, the ultimate fate of the internalized 
complex is an area of differing opinions. Several investigators have 
found that the "tracer" insulin associated preferentially with 
lysosomes in isolated hepatocytes (84,89,90), perfused rat liver (91), 
and cultured 3T3-L1 adipocytes (78). Similarly, a photoaffinity probe 
covalently attached to the insulin receptor was shown to localize to 
the lysosomes (83). A strong source of support for this concept is 
the finding that lysosomal stabilizing agents (e.g. chloroquine and 
ammonium chloride) decreased the degradative rate of internalized 
insulin (74,76,80,92,93). Further, it appears that insulin is not 
released from the cell until it is degraded (94). 
In contrast, in perfused rat liver, Bergeron et a 1 (95) found 
that labeled insulin preferentially associated with the Golgi 
apparatus. Wang et a 1 (81) presented similar findings using a 
photoaffinity probe covalently bonded to the insulin receptor. Posner 
(96), Kono et a 1 (77), and Suzuki and Kono (97) suggest that labeled 
insulin associates with a "third type" of membrane-bound compartment 
with properties intermediate between the Golgi apparatus and the 

31 
lysosome. Goldfine et a 1 (98) found insulin localized to the 
endoplasmic reticulum and nuclear membrane in the cultured human 
lymphocyte. The source of the discrepancies in the data are unclear, 
but may involve differences in intracellular routing of the 
internalized insu1in-receptor complex under differing conditions (see 
below - recycling). 
Recent studies with alpha 2-macroglobulin (99) and low-density 
lipoprotein (100) have shown that these two factors, which are also 
internalized by receptor-mediated endocytosis, were initially 
associated with a prelysosomal compartment, which has been called an 
nendosome"(101), "receptosome"(99 ) , or "sorting vesicle"(100) . 
Subsequently, the alpha 2-macrog1obu1in was transferred to lysosomes. 
Although an association of insulin with this structure has not been 
demonstrated yet, these results may provide a mechanism to account for 
the discrepancy of findings with insulin internalization. 
Terris and Steiner (102) first proposed that insulin degradation 
was a receptor-mediated process. Current data, showing association of 
internalized insulin with lysosomes and subsequent degradation, 
indicates that receptor linked insulin degradation may result from 
receptor mediated endocytosis and internalization. However, there 
also appears to be another soluble degradative enzyme system which 
does not require binding (51). The relative contribution of these two 
processes in insulin degradation in vivo is unclear. 
It has also been proposed that insulin-induced receptor loss, 
down-regulation", is linked to receptor-mediated internalization 
( 73,103). Gorden et a 1 (48) pointed out several factors that suggest 
that insu1in-induced receptor loss is linked to receptor-mediated 
internalization: 1) membrane microheterogeneity, where classes of 
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receptors may occur in specific domains, could explain the specificity 
of down-regulation by internalization, 2) the concentration of ligand 
necessary to induce receptor loss is inversely proportional to the 
magnitude and rate of internalization of the ligand, and 3) 
conditions which induce receptor loss are associated with an increase 
in pinocytotic rate of the cells. 
While it has been demonstrated quite convincingly that growth 
hormone-induced down regulation and hormone degradation are coupled to 
ligand internalization (104), the picture with insulin is less clear. 
While evidence exists to support the claim that insulin receptor 
down-regulation and insulin degradation are coupled to internalization 
(82), certain discrepancies in the data exist. First, 
insu1in-receptor complex internalization and insulin degradation are 
rapid processes, usually occurring within minutes, whereas 
down-regu1ation requires hours. Secondly, in certain cell types, 
there exists a poor correlation between the extent of insu1in-induced 
down regulation and the extent of insulin-receptor internalization 
(85). Therefore, the link between receptor-mediated endocytosis of 
the insulin-receptor complex and down-regulation may involve other 
mechanisms. 
To complicate the already complex story of insulin binding 
presented above, there has been convincing evidence presented that the 
insulin receptor is not only internalized, but that it is "recycled" 
back to the cell surface. Using a heavy isotope density shift 
technique, Krupp and Lane (94) showed in the chick liver cell that 
there existed different pathways for degradation of insulin and its 
receptor. They found that receptor-mediated insulin degradation 
occurred via an endocytotic lysosomal path at a rate two hundred times 
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as great as degradation of the insulin receptor, and concluded that 
the insulin receptor is recycled at least two hundred times before 
degradation. Marshall et a 1 (76) presented interesting evidence in 
support of a receptor recycling mechanism in rat adipocytes. Fehlman 
et a 1 (85), using covalently linked photoaffinity probes, demonstrated 
that the insu1in-receptor complex was initially internalized, but then 
gradually reappearred at the level of the plasma membrane, providing 
direct evidence for recycling of the insulin receptor. 
While these findings add to the complexity of the overall 
picture, they also may supply a unifying mechanism to account for the 
many disparate findings. While the internalized insulin is apparently 
destined for degradation, the receptor may enter the degradative 
pathway or be recycled to the cell surface. The data suggest that at 
some point after internalization of the insulin-receptor complex, 
insulin targeted for degradation must separate from receptor destined 
for recycling (27). It has recently been proposed that the 
pre-1yso soma 1 compartment ("endosome", "receptosome" , or "sorting 
vesicle") may serve as a site where the internalized ligand seperates 
from the receptor (101,105). Subsequently, the internalized ligand 
would be transferred to lysosomes for degradation and the receptor 
would be either degraded or recycled back to the cell surface. Tycko 
and Maxfield (105) demonstrated with microscopic spectrof1uorography 
that the prelysosomal compartment has a low pH (pH approx. 5.0). This 
could provide a mechanism for the dissociation of the ligand from the 
receptor, since insulin dissociates from its receptor at low pH (105). 
As Reed (27) points out, the role the timing of the dissociation of 
insulin from its receptor plays in determining whether receptor 
degradation or recycling occurs is unknown. The postulated recycling 
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mechanism also supplies a mechanism accounting for the differing 
kinetics of receptor-mediated internalization of the insu1in-receptor 
complex and degradation of the hormones and the longer time required 
for insulin induced down-regu1ation (76). Therefore, net receptor 
concentration on the cell surface will represent a dynamic equilibrium 
between the rate of membrane internalization, receptor degradation, 
membrane recycling, and the rate receptors are synthesized, 
transported, and inserted into the plasma membrane (51). 
On the basis of the above presentation, it is hoped that the 
reader will appreciate the complexity of the determinants of 
insu1in-insu1in receptor interaction. It is obvious that insulin can 
directly alter the cellular determinants of insulin binding: receptor 
affinity and receptor concentration. It is therefore apparent that 
while a simple bimolecular model is a useful framework, it has marked 
limitations in describing the complexity of the insulin binding 
interaction . 
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3 ) Transformation of Insulin-Receptor Interaction 
into a Transmembrane Signal 
The insulin receptor is an "integral" membrane glycoprotein. 
Using freeze-fracture techniques, ferritin-insu1in molecules were 
found to be associated solely with the external leaflet of the plasma 
membrane (32). Direct study of inverted membrane vesicles, prepared 
from adipocytes, has also shown that insulin receptors are solely on 
the external surface of the plasma membrane (107). Although there 
exists a great deal of interest in the mechanism of signal generation, 
there has not been an abundance of data in this field, primarily 
because membrane physiology and membrane biophysics are relatively new 
fields. 
One finding that is highly substantiated is that while the 
"coupling" mechanism between insulin-binding and insulin action is a 
function of the concentration of insulin-receptor complexes, this is 
not a direct relatonship. Kono and Barham, in 1971 (108), were the 
first to show that maximal stimulation of an insulin end action, 
glucose oxidation, required that only two percent of the insulin 
receptors be occupied. Using a complimentary DNA probe to measure the 
synthesis of mRNA for the enzyme phosphoenolpyruvatecarboxykinase, in 
a well differentiated hepatoma cell line, Andreone et a 1 (109) have 
shown that maximal inhibition of mRNA synthesis occurred at a receptor 
occupancy of less than one percent. This phenomenon led to the 
proposal of "excess" or "spare" receptors. By all criteria that have 
been employed, these "spare" receptors are identical to the occupied 
receptors. All receptors on the cell surface are capable of 
generating a biological response, but at any one point only a fraction 
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need to be occupied for a maximal effect (40). Bar (11) suggests a 
(and thereby a type of regulatory mechanism) differential 
of the myriad of insulin's intracellular effects based on the 
fractional receptor occupancy. 
In systems with spare receptors, when a progressive reduction in 
the total number of receptors occurs (e.g. insulin-induced 
down-regulation), there will be a progressive decrease in insulin 
sensitivity (a shift of the dose-response curve to the right). 
However, no decrease in maximal responsiveness will occur until all of 
the "spare" receptors have been "consumed", provided the ambient 
hormone concentration can be increased sufficiently to compensate 
(40). 
The physiologic role of "spare" receptors is uncertain. Kono and 
Barham (108) proposed that cells equipped with large numbers of 
receptors were highly sensitive to insulin, based on the application 
of the law of mass action to the insulin-receptor interaction. 
While the physiology of the "coupling" mechanism has been 
elucidated by these studies, the actual mechanism for generation of a 
transmembrane signal is enigmatic. Anti-insulin receptor antibodies 
can both inhibit and mimic insulin action. Kahn et a 1 (110) have 
shown that the ability of these antibodies, which bind specifically to 
the insulin receptor, to mimic insulin action requires bivalency. 
Monovalent Fab fragments, generated by pepsin digestion of the intact 
XgG molecule, were able to specifically inhibit insulin action, but 
were unable to mimic insulin's bioeffects. Reconstitution of the Fab 
fragments by the subsequent addition of anti-IgG allowed restoration 
of the insulin-like effect of the antibody. Kahn et a 1 (110) also 
showed that low concentrations of anti-insulin antibodies augmented 
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the effect of submaximal concentrations of insulin. They interpret 
these results as suggesting that insulin receptor aggregation or 
clustering may be an important component in the expression of insulin 
action. They further suggest, and provide supporting evidence, that 
microtubules and microfilaments are not involved in this process of 
aggregation. 
Using ferritin-1 abeled insulin and freeze-fracture techniques, 
Orci e t a 1 (32) have found that insulin-receptor complexes in plasma 
membranes can exist singly or in clusters with three to twelve 
ferritin-insu1in molecules. In the fat cell, clusters of 
ferritin-insu1in complexes were reported to exist prior to fixation, 
suggesting that these are naturally occurring groups (111). Using 
fluorescently labeled insulin, Schlessinger et a 1 (112) have 
demonstrated mobility of the insulin receptor complex directly by 
laser-bleaching and image intensification microscopy. In mouse 
fibroblasts, they have shown that f1uorescent1y labeled insulin binds 
diffusely over the cell surface at four degrees Centigrade. At higher 
temperatures, the insulin receptor complexes were found to be mobile 
and formed "clusters" or "patches" (112). In cultured human 
lymphocytes, I<125>-insu1in bound diffusely initially at low 
temperatures, but then redistributed toward the Golgi pole of the cell 
and formed a discrete "cap" on the cell surface (113). 
The ultrastructural mechanism responsible for this aggregation is 
unclear. As stated above, it is not mediated by microfi1 aments or 
microtubules (110). It has been postulated that when insulin binds to 
the plasma membrane, its local concentration may approximate 
micromolar levels, a concentration at which insulin in solution 
dimerizes or aggregates (110). This has led to the proposal that 
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insu1in-insu1in interactions, through any of a variety of sites, 
mediate receptor aggregation (114). However, if this aggregation is 
important for activity, it must differ from aggregation in solution, 
since insulins which do not dimerize are biologically active, e.g. 
guinea pig insulin (55). Jarret et a 1 (115), have shown that the use 
of either of the two thiol reagents, cytochalasin B and 
N-ethylma1eimide , or the reducing agent dithiothreito1 , caused the 
disruption of receptor aggregates. They therefore suggest that 
receptor aggregation is mediated by disulfide bonds which are in a 
rapid equilibrium of association and disociation. Therefore, 
disulfide bonds may play a role as the u11rastructura 1 mechanism in 
receptor aggregation. 
In summary, on the basis of these studies of receptor 
aggregation, it seems justifiable to conclude, as Gorden et a 1 (51) 
have, that insulin may: 1) bind initially and preferentially to a 
specialized region of the cell surface and is not mobile in the plane 
of the plasma membrane; 2) may bind initially and preferentially to a 
specialized region and still maintain mobility in the plasma membrane; 
or, 3) may bind diffusely and then cluster by diffusion within the 
plasma membrane into specialized regions. This clustering would 
supply a mechanism for the specificity of the subsequent 
internalization process. 
This aggregation may play a role in the mechanism of 
transmembrane signal generation. The most substantial evidence 
supporting receptor aggregation as a method of generating a 
transmembrane signal are the antibody studies of Kahn et a 1 (110). 
However, because of the rapidly evolving nature of this area of 
research, one must keep an open mind in evaluating new evidence. 
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Preliminary data in subcellular systems suggests that the beta subunit 
of the insulin receptor is a protein kinase (116) capable of 
phosphorylating itself 36). The role this plays in transmembrane 
signalling, and whether it is complimentary to or precludes receptor 
aggregation in transmembrane signalling, is receiving intense study by 
a number of laboratories. 
4) Generation of Intracellular Message (or Messengers) 
The search for the intracellular mechanism of insulin action is 
complicated by its myriad of intracellular effects (see Table III). 
There are two distinct theories for the generation of insulin's 
membrane and intracellular effects. The first theory is based on the 
internalizaion of the insulin-receptor complex and suggests that 
insulin action is mediated by this internalized complex, the 
internalized receptor, the internalized hormone, or fragments of these 
molecules generated by degradation. The second proposal is based on 
the generation of an intracellular "second messenger", analagous to 
cyclic adenosinemonophosphate (cAMP) in adenylate cyclase systems. 
The data supporting the intracellular internalization of insulin 
are unequivocal. Steiner (117) and Goldfine (118) were the first to 
propose that internalized insulin, or a bioactive degradation product 
of insulin, acts as the "second messenger" of insulin action. As 
discussed previously, the intracellular site of localizaion of 
"internalized" insulin is still controversial (lysosomes, Golgi 
apparatus, "endosome", and/or nucleus). Regardless, a substantial 
part of the internalized insulin is degraded (97,119). This 
degradation is inhibited by lysosomotropic agents (92,97). 

40 
Table iii - Effect of Insulin on Enzymes - from (30) 
ENZYME ACTIVITY METABOLISM 
1. Enzymes of Glucose Metabolism and Storage 
Glucokinase Increase Increase Synthesis 
Hexokinase II Increase Increase Synthesis 
(transcription) 
Phosphofructokinase Increase Increase Synthesis 
(isozyme L2) Decrease degradation 
Pyruvate Kinase Increase Not sensitive to actinomycin D 
or puromycin 
Glucose-6-phosphate Increase Increase Synthesis 
dehydrogenase 
Pyruvate dehydrogenase Increase Dephosphorylation 
Citrate cleaving enzyme Increase Increase Synthesis 
Malic enzyme Increase Increase Synthesis 
Glycogen synthetase Increase Dephosphorylation 
PEP-carboxykinase Decrease Decrease Synthesis 
Fructose-1,6-diphosphatas e Decrease Not sensitive to actinomycin D 
or puromycin 
G1ucose-6-phosphatase Decrease Decrease Synthesis 
Pyruvate carboxylase Decrease Decrease Synthesis 
2. Enzymes of Lipid and Sterol Turnover 
Acetyl-CoA carboxylase Increase Dephosphorylation (?) 
Fatty acid synthetase Increase Increase Synthesis 
HMG-CoA reductase Increase Increase Synthesis 
Adipocyte lipase Decrease Decrease Synthesis 
3. Enzymes of Protein and Nucleic Acid Turnover 
Forinimino transferase Decrease ? 
Ornithine decarboxylase Increase Not inhibited by cycloheximide 
Tyrosine aminotransferase Increase Increase Synthesis, Increase Trai 
Serine dehydratase Decrease Decrease Synthesis 
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While internalization does occur, there are no strong data 
supporting insulin, the receptor, or fragments of these molecules as 
intracellular messengers. In experiments where internalization or 
lysosomal degradation (51) were impaired, there appeared to be no 
inhibition of insulin action. Secondly, it has not been possible to 
isolate small fragments of the insulin molecule which retain 
bioactivity (120). Third, although insulin receptors have been found 
on intracellular organelles, there is no evidence that these are 
biologically active, and they more likely represent receptors in the 
process of synthesis and degradation (120). Finally, anti-insulin 
receptor antibodies, which are able to mimic insulin action in many 
respects, are also internalized by the cell and associated with 
lysosomes. As Kahn stated (120), it seems unlikely that a similar 
degradation product would be generated from both insulin and the 
antibody. Therefore, current evidence seems to argue against 
internalization of the insu1in-receptor complex as a mechanism for 
generating insulin's intracellular actions. 
The search for a true "second messenger" of insulin action has 
focused on a series of possible mediators including hyper polarization 
of the cell membrane, changes in calcium ion flux, and cyclic 
nucleotides. The activity of many enzyme systems are controlled by 
phosphorylation and dephosphory1ation , and the hormones which interact 
with the adenylate cyclase system are thought to mediate at least some 
of their effects by this method (40). Recent evidence suggests that 
insulin may also mediate some of its actions by changes in protein 
phosphorylation and dephosphorylation. Working backwards from an 
intracellular site of insulin action, using inhibition of protein 
kinase as an assay, Larner et a 1 (121) were able to identify a peak of 
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a Sephadex G-25 column with insulin activity. Characterization of 
this peak revealed a peptide(s) with molecular weight(s) of 1000-2000 
daltons (122). With the aid of high voltage electrophoresis, Cheng et 
a1 (123) were able to identify two separate peptides which increased 
dephosphory1 ation ("mediator") and increased phosphorylation 
("anti-mediator"). 
"Mediator" peptide has been shown to inhibit cyclic AMP-dependent 
protein kinase, stimulate glycogen synthase phosphoprotein 
phosphatase, stimulate mitochondrial pyruvate dehydrogenase 
phosphoprotein phosphatase, stimulate endoplasmic reticulum 
cAMP-phosphodiesterase , activate high affinity (Ca + + -Mg + +)-ATPase, and 
also activate the ATP-dependent calcium ion transport in adipocyte 
plasma membrane (121). The "mediator" has been shown to exist in 
intact muscle (122), rat adipocytes (124), IM-9 cultured human 
lymphocytes (125), and rat liver membranes (126). Therefore, this 
substance exists in a wide variety of tissues and has a wide variety 
of effects consistent with insulin action, and the term "mediator" 
seems appropriate. 
The "anti-mediator" was first postulated to exist on the basis of 
biphasic responses in test systems, where low concentrations of 
insulin caused a response that was reversed at higher concentrations. 
Turakulov et a 1 (127) found that insulin treatment of rats produced a 
low molecular weight substance in the cytosol of the liver, which 
caused a biphasic response in calcium uptake. In an adipocyte 
subcellular system, Seals and Jarret (128) demonstrated a biphasic 
dose-response curve for activation of pyruvate dehydrogenase in 
response to insulin, concanavalin A, or anti-insulin receptor 
antibody. Using adipocyte plasma membranes, Seals and Czech (129) 
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have shown that incubation with increasing concentrations of insulin, 
or incubation for increasing periods of time, yielded a supernatant 
material that produced a biphasic stimulation of pyruvate 
dehydrogenase. Saltiel et al (130) obtained similar results with 
liver plasma membranes. The most convincing evidence for the 
existence of "anti-mediator" was supplied by Larner's group. The 
fraction from the Sephadex G-25 column which they isolated, discussed 
above, produced a biphasic effect on glycogen synthase phosphatase. 
However, when Cheng et a1 (123) subfractionated this isolate into the 
two components, the "mediator" fraction contained the ability to 
stimulate the phosphoprotein phosphatase and the "anti-mediator" 
fraction inhibited this enzyme, and there was no biphasic response 
obtained in either of the subfractions. Therefore, there exists 
evidence for the existence of a "mediator" and an "anti-mediator". 
Despite the characterization of these properties of the mediator 
mechanism, the identity of the "mediator" is unclear. Larner et a 1 
(131) proposed that the mediator is a peptide, or peptide-1ike, on the 
basis that: 1) after acid hydrolysis a number of amino acids were 
generated, 2) low concentrations of trypsin appeared to be able to 
generate the mediator, thus indicating that it is probably formed 
proteo1ytica11y, and 3) insulin action was blocked by 
tosy11ysy1ch1oromethy1ketone, a proteolytic enzyme inhibitor. In 
contrast, Jarret et a 1 , who initially also thought that the 
"mediator" was a peptide (132), now seem to think that it is not a 
peptide and may instead be a phospholipid derivative (87). Further 
research in this fascinating area is necessary to confirm the 
existence of these mediators by other investigators, as well as to 
more accurately delineate their range of intracellular actions, and to 

44 
provide a final identification of the "mediator" and "anti-mediator". 
5) Chemical Modification of Appropriate Enzymes and Transport Systems 
to Effect Insulin's Actions 
Insulin's actions can be subdivided into three tiers on the basis 
of the interval between insulin binding and insulin action (121). 
Insulin initiates a rapid set of actions, within minutes, at the cell 
membrane which includes the transport of hexoses, ions, amino acids 
and nucleosides. The second set of actions occurs over the course of 
minutes to hours and involves a shift in the metabolic machinery of 
the cell into the anabolic mode by regulating lipolysis, proteolysis, 
glycolysis, and gluconeogenesis. The final action of insulin is to 
augment growth which takes place over an even longer period of time. 
A complete description of insulin's metabolic and regulatory 
effects is far beyond the scope of this review (for partial list - see 
Table III). However, a brief discussion of the current understanding 
of its mechanism of action on glucose transport is in order, since 
this is one of the main parameters that will be examined in the 
experimental study. 
Glucose is transported across the cell's plasma membrane by 
facilitated diffusion in both the basal and insu1in-stimu1 ated states 
(133). Kinetic studies revealed that insulin action increased the 
maximum velocity (Vmax) of the transport system and did not affect the 
Michea1is-Menten constant ( 134,135). Wardzala et a 1 (133) have shown 
that insulin stimulation increased the amount of binding of tritiated 
cytochalasin B, a fungal metabolite which binds to the glucose 
transport system and inhibits it. They concluded that insulin caused 
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an increase in the number of glucose transport sites in the plasma 
membrane of the rat adipocyte. Extending the use of this technique, 
they have subsequently found that insulin stimulation causes a 
translocation of glucose transport sites from the microsomal membrane 
portion of the cell, with a minimal three-fold increase in the number 
of glucose transport units in the plasma membrane. Further, they 
found that this effect occurred as rapidly as they could measure it - 
less than five minutes, and proposed that it may represent the 
mechanism of insulin's acute stimulatory action on glucose transport. 
Suzuki and Kono (136) have presented similar data, and through the use 
of enzymatic membrane markers, have inferred that the intracellular 
site of the glucose transport units is the Golgi apparatus. In 
summary, insulin has been found to mediate some, if not all, of its 
effect on glucose transport by causing a rapid translocation of 
glucose transport units from the microsomal membrane portion of the 
cell to the cell surface. 
6) Termination of the Insulin-Receptor Signal 
The problem of the relationship between insulin receptor 
occupancy and the termination of insulin action has not been addressed 
until recently. The majority of previous kinetic studies were more 
concerned with the lag period between insulin binding and the onset of 
its actions. 
Early studies by Crofford (137) indicated that a rapid reduction 
in extracellular insulin led to a rapid decrease in glucose oxidation. 
Similarly, Glieman et a 1 (138) concluded that receptor desaturation 
was the rate-limiting step in the termination of insulin's effect on 
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lipogenesis. In contrast, more recent work by Ciaraldi and Olefsky 
(139,140) indicated that receptor desaturation does not lead to the 
immediate termination of insulin action. They concluded that receptor 
desaturation and termination of insulin action are independent 
processes. The most recent studies, by Haring et a 1 (141), which 
measured the inactivation of glucose transport in rat adipocytes, 
supported these latter findings. Furthermore, through the use of 
rate-limiting insulin concentrations, Haring et a 1 found that this 
phenomenon was not the result of occupancy of "spare" receptors. They 
concluded that a post-receptor mechanism controls the termination of 
the insulin effect, and that the speed of the termination process is 
related to the fractional receptor occupancy and the functional 
activity of the glucose transport mechanism (or other insulin end 
action). Therefore, while insulin receptor occupancy is necessary to 
initiate insulin's actions, persistent receptor occupancy by the 
ligand is not required for a continued effect. 
In summary, our understanding of the complexity of 
hormone-receptor interaction has evolved with the development of 
techniques that have allowed the investigator to examine individual 
steps in the mechanism of insulin action. The purpose of this 
overview of insulin-insulin receptor interaction is to provide an 
appreciation of the complexity of the insulin endocrine "system" and 
to provide a foundation for understanding the studies of the syndrome 
of insulin resistance associated with acanthosis nigricans as 
presented in this report. 

E) Extreme Insulin Resistance Associated with Acanthosis Nigricans 
1) Clinical Characteristics 
In 1975, Flier et a 1 (142) described a group of six patients 
with severe insulin resistance and the skin disorder acanthosis 
nigricans. Three of these patients were found to have antibodies in 
their serum which inhibited insulin binding to a variety of tissue 
types. These patients were designated as having the "Type B syndrome 
of insulin resistance and acanthosis nigricans", in order to 
differentiate them from the other group of patients ("Type A") who did 
not have inhibitory antibodies in their serum. By 1982, approximately 
twenty-five cases of Type B insulin resistance had been reported in 
the world's literature (35). The syndrome is an autoimmune disorder 
characterized by: 1) findings consistent with an immunologic disorder; 
2) the skin disorder acanthosis nigricans; 3) abnormal glucose 
tolerance with extreme insulin resistance; and 4) the presence of 
autoantibodies to the insulin receptor - Anti-R Ab (143). 
Furthermore, none of the known causes of insulin resistance, such as 
obesity, high titers of anti-insulin antibodies, lipoatrophy, 
Cushing's disease, or acromegaly accompany this disorder (144). 
The disease primarily affects adults, although the age range 
varies widely from twelve to sixty-five years (145). There is a 
marked female predominance, as is often the case with autoimmune 
disorders (for interesting discussion of gender differences in 
autoimmunity - see ref.146). The disease also shows a prediliction 
for non-caucasian races. Over fifty percent of the patients have been 
blacks from North America or the Carribean islands, although it is 
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also found in Japanese, Mexicans, and Caucasians from North America 
and Europe (35). 
These patients typically have immunological findings consistent 
with an autoimmune disease. In about one third of the cases some 
"classic" autoimmune disease co-exists (147), such as systemic lupus 
erythematosis (SLE), Sjogren's syndrome, or ataxia telangiectasia. In 
the remainder of cases, various findings consistent with, but not 
diagnostic of, an autoimmune disorder have been found to exist to 
varying degrees, including: alopecia, vitiligo, proteinuria, enlarged 
salivary glands, arthralgias and arthritis, splenomegaly, leukopenia, 
elevated erythrocyte sedimentation rate, positive anti-nuclear antigen 
test, hypergammaglobulinemia, and high titers of anti-DNA and anti-RNA 
antibodies (147). These immunological findings, however, do not 
correlate well with the clinical course of the disease (145). 
The skin disorder acanthosis nigricans, known to be associated 
with various endocrinopathies and malignancies (148), is found in 
almost all patients. However, it varies considerably from barely 
detectable to severe involvement of the trunk and face (35). The 
acanthosis nigricans is most likely related to the endocrine disorder 
of extreme insulin resistance in these patients, as only one patient 
had an occult malignancy (145). Although the etiology of the skin 
disorder is unknown, in most cases, it appears to follow the clinical 
course of the hyperinsulinemia and glucose intolerance abnormality 
(145) . 
The hallmark of the Type B syndrome is the extreme resistance to 
endogenous and exogenous insulin (143). The patients typically have a 
baseline hyperinsulinemia, with a basal level of serum insulin of 80 - 
950 microunits of insulin per mililiter (normal 11 +/- 4 
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microunits/m1), which may, in some cases, overcome the insulin 
resistance (143). In one case, beta cell hyperplasia has been found 
at autopsy (149), whereas in another case, no abnormality in the 
pancreas or islet cells was noted (150). These patients are also 
incredibly resistant to exogenous insulin therapy. One patient in the 
literature, who was most likely afflicted with this disorder, received 
177,500 units of insulin in an attempt to control hyperglycemia (151). 
The abnormal carbohydrate metabolism found in this syndrome is 
subject to variability both between patients and over the course of 
the disease in an individual patient. The most common initial 
presentation has been symptomatic diabetes, with polydipsia, 
polyphagia, polyuria, and weight loss (35). The patients, however, 
rarely develop ketoacidosis (143). In contrast, it is also possible 
for these patients to present with hypoglycemia (152). Furthermore, 
over the course of the illness , glucose intolerance and insulin 
resistance may spontaneously improve (150). Of the thirteen cases 
with Anti-R Ab followed by Taylor et a1 ( 152) , symptomatic 
hypoglycemia occurred at some point in the clinical course of five of 
these cases. The mortality rate of those patients who developed 
hypoglycemia was high, with three of the five patients dying, and in 
two cases the hypoglycemia seemed to be the cause of death (152). 
A major defect in these patients responsible for the extreme 
insulin resistance is a marked decrease in insulin binding to cells. 
Although the extent of inhibition varies, binding is typically 
diminished to approximately twenty-five percent of normal (153,154). 
This has been observed in these patients’ circulating monocytes 
(142,153,154), in adipose cells obtained by gluteal biopsy (153), and 
in circulating erythrocytes (153). Therefore, insulin receptor 
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"blockade" by the antibodies seems to be a generalized phenomenon in 
the Type B patients (153). Binding studies performed on circulating 
monocytes of these patients showed that the fundamental defect was a 
decrease in receptor affinity, with no substantial alteration in 
receptor number (142,154,155). Type B patients' cells also lack 
negative cooperativity binding characteristics (142,153,154). Kinetic 
analysis of binding revealed that this decrease in receptor affinity 
and loss of negative cooperativity was due to an increase in the 
spontaneous rate of dissociation of insulin from the receptor (155). 
The suspicion that these binding alterations were caused by an 
autoimmune disease was fostered by the clinical findings consistent 
with an immunological disorder (20). This led to the search for a 
serum factor capable of inhibiting insulin binding. This serum factor 
was identified by the ability of patients' serum to inhibit binding to 
IM-9 cultured human lymphocytes (20). The serum component was 
identified as an immunoglobulin of the IgG class by multiple criteria, 
including precipitation by 33% ammonium sulfate, characteristic 
behavior on G-200 Sephadex gel filtration and DEAE chromatography, and 
immunoprecipitation with specific anti-human immunoglobulin (20). 
Furthermore, the immunoglobulins were shown to be polyclonal by their 
reactivity with both anti-kappa and anti-lambda serum (20). The 
binding inhibition is due to the Fab fragment, not the Fc fragment of 
the molecule (20). 
The underlying insulin receptor in these patients appears to be 
structurally and fuctionally normal, as far as can be determined by 
the sensitivity of current tests (155). This is based on many lines 
of evidence. First, subjecting monocytes from these patients to an 
acid-wash procedure, known to remove cell bound antibodies, results in 
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an increase in insulin binding toward normal and a restoration of 
negative cooperativity (155). Lymphocytes and fibroblasts from these 
patients that have been cultured have shown no differences in receptor 
affinity or receptor number compared to normal cultured cells (155). 
In one Type B patient who underwent a spontaneous remission, 
associated with a decrease in antibody titer to an undetectable level, 
the insulin receptors showed normal binding by kinetic, equilibrium, 
and specificity binding criteria. Moreover, exposure of her cells to 
anti-insulin receptor antibodies showed the same inhibition of binding 
as normal cells (155). Furthermore, in one patient in whom the 
autoantibodies were removed by repeated plasma exchange therapy, 
insulin binding to the patient’s cells improved dramatically and 
patient's clinical features were mildly ameliorated (154). Thus, by 
all these criteria, the underlying insulin receptor appears to be 
normal in Type B patients. 
2) In Vitro Characterization of Anti-Receptor Antibodies 
The Anti-R Ab has been demonstrated to inhibit specific insulin 
binding to cultured human lymphocytes (IM-9) and isolated rat 
adipocytes by up to 95 percent (156,157). Scatchard analysis showed 
that in most cases this was consistent with a loss in receptor 
affinity rather than a loss in receptor number (156,157). Anti-R Ab 
was also able to induce a loss of negative cooperativity , similar to 
that which occurs in the patient's own cells. These effects of Anti-R 
Ab on binding to the insulin receptor were time and temperature 
dependent, and the effects were only slowly reversed (156). The 
Anti-R Ab seems to bind with an extremely high affinity, since it is 
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not removed by simple washing (147) and requires a longer time to 
dissociate from the receptor, with a dissociation half-time of 10-12 
hours at 37' C (158). 
There is a great deal of evidence along many diverse lines that 
the Anti-R Ab binds directly to the insulin receptor, as opposed to a 
nearby membrane constituent. First, Anti-R Ab blocks insulin binding 
in virtually all cell types and species that have been tested 
(120,157). Therefore, if Anti-R Ab did not recognize the receptor 
directly, it would have to be recognizing some other membrane 
component which is extremely well conserved in evolution, both in its 
structure and in its linkage to the insulin receptor (120). Secondly, 
I<125>-labe1ed anti -receptor antibody binds to a variety of cells in 
direct proportion to their insulin receptor concentration, and this 
binding is inhibited by insulin analogs in order of their affinity for 
the insulin receptor (12,159). Third, the Anti-R Ab quantitatively 
precipitates the solubilized insulin receptor (160). This property of 
the Anti-R Ab has been used to immunoprecipitate insulin receptor 
subunits that have been labeled with surface iodination with 
I< 1 25>-insu1in and the cross-linking agent disuccinimidy1 suberate 
(161) or that have been labeled biosynthetica 11y with S<35>-methionine 
(162) , thereby providing direct evidence that the antibody binds 
directly to the insulin receptor. Finally, it has been shown that 
Anti-R Ab is able to mimic many of insulin's actions in a wide variety 
of cell types (see Table IV). 
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Table IV - Insulin-like Effects of Anti-Insulin Receptor Antibodies 
- from Ti92l 
Stimulation of 2-deoxyglucose transport, 
glucose incorporation into lipid, 
and glucose oxidation to C02 
Stimulation of amino acid incorporation into protein 
Inhibition of lipolys is 
Activation of glycogen synthetase 
Inhibition of phosphorylase 
Activation of pyruvate dehydrogenase and 
Acetyl-CoA carboxylase 
Stimulation of insulin's effect on protein phosphorylation 
5T3-L1 FATTY FIBROBLASTS 
Stimulation of 2-deoxyglucose transport and 
glucose oxidation to C02 
Activation of lipoprotein lipase 
MUSCLE, 
Stimulation of 2-deoxyglucose transport and 
glucose incorporation into glycogen 
Activation of glycogen synthetase 
LIVER 
Stimulation of amino acid (AIB) transport 
PLACENTA 
Stimulation of insulin's effects on protein phosphorylation 
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In isolated rat adipocytes, the Anti-R Ab has been demonstrated 
to stimulate glucose transport and metabolism (157), stimulate amino 
acid incorporation into protein (147), stimulate pyruvate 
dehydrogenase and acetyl-CoA carboxylase (163), inhibit lipolysis 
(147), and alter protein phosphorylation (163). Anti-R Ab has been 
demonstrated to mimic insulin action in human adipose tissue (153), 
cultured 3T3-L1 fatty fibroblasts (164), mouse soleus muscle 
(165,166), and liver (145). In addition to these actions which mimic 
insulin's "early" effects, Anti-R Ab has been shown to mimic one of 
insulin's "late" actions, by increasing the activity of lipoprotein 
lipase in 3T3-L1 fatty fibroblasts (167). In these actions, the 
antibody acts through the same mechanism as insulin, since the 
response to submaximal concentrations of insulin is augmented by 
Anti-R Ab, and vis versa , but maximal stimulation induced by either 
agent is not accentuated by the other agonist. Indeed, in its 
stimulation of glucose transport, Anti-R Ab has been shown to increase 
the number of glucose transport units in the plasma membrane, in a 
manner directly analagous to insulin (168). 
The single effect which Anti-R Ab has not been able to mimic is 
the incorporation of thymidine into DNA, suggesting that the antibody 
is unable to mimic insulin's growth effects (169). However, recent 
evidence utilizing anti-receptor Fab blocking fragments suggests that 
these effects of insulin are not mediated through the insulin 
receptor, but instead are mediated through binding to the 
mu 11ip1ication-stimu1ating activity (MSA) receptor (169). 
The ability of Anti-R Ab to mimic insulin's interaction with 
cells is not limited to an ability to induce insulin's metabolic 
effects. On lymphocytes, it has been shown that fluorescein-labeled 
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antibodies aggregate and "cap" over one pole of the cell (170). As 
noted previously, the finding that Anti-R Ab requires bivalency to 
maintain bioactivity is the strongest evidence in support of receptor 
"aggregation" or "patching" in the generation of a transmembrane 
signal (110). I< 1 25>-1 a be 1ed anti-receptor antibody is also 
internalized into cells, associates with lysosomal structures, and is 
degraded. This degradation is inhibited by lysosomal stabilizing 
agents (171). I<125>-labeled Fab fragments are also internalized by 
the cell and degraded (172). The fact that these antibody fragments 
are internalized and degraded, but are not bioactive, is strong 
evidence against the process of "internalization" as a mechanism for 
generating an intracellular second messenger of insulin action. 
Therefore, it can be seen that the anti-insulin receptor antibodies 
act, as far as can be determined, in a manner completely analagous to 
insulin. This strong similarity has prompted some investigators to 
propose that the insulin receptor contains all of the information 
necessary for generating insulin's intracellular and membrane actions, 
and that the insulin acts solely to trigger the receptor to express 
itself (40). 
F) Purpose of Present Study 
The ability of Anti-R Ab to mimic virtually all of the actions of 
insulin for which it has been evaluated is in distinct contrast to the 
clinical presentation of severe insulin resistance in Type B patients. 
These two findings are difficult to reconcile. In 1979, Karlsson e t a 1 
(158) showed that the insulinomimetic effect of Anti-R Ab was an acute 
phenomenon. This study employed cultured 3T3-L1 fatty fibroblasts, a 
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cell line which does not undergo "down-regulation" (173), in order to 
dissociate the interference of this effect. The Anti-R Ab caused an 
acute stimulation of glucose transport and glucose oxidation which 
peaked between 30 and 120 minutes. Subsequently, the stimulatory 
effect decayed and after six hours, a state of severe insulin 
resistance prevailed (158). These "desensitized" cells had a marked 
decrease in the maximal response to insulin. This decay was not 
accompanied by any detectable change in insulin binding. 
Desensitization involves resistance to all agents which act 
through the insulin receptor, including concanavalin A, insulin, and 
anti-insulin receptor antibodies (158). However, the actions of 
Vitamin K-5 and spermine, two agents that stimulate glucose metabolism 
through a process independent of the insulin receptor, were unaltered 
in desensitized cells, suggesting that the glucose metabolic machinery 
was intact (164). The desensitization process required bivalency of 
the antibody, also a requirement for the other biologic effects of the 
Anti-R Ab (164). Furthermore, chloroquine (lysosomal stabilizing 
agent), cycloheximide (protein synthesis inhibitor), colchicine 
(inhibits microtubular function), and cytochalasin E (inhibits 
microfi1ament function) had little effect on the induction of, or 
recovery from, desensitization (164). These investigators concluded 
that desensitization is not merely due to the inhibition of insulin 
action by a "blockade" effect, but they suggest that it is a complex 
process involving a decreased ability of the receptor to generate a 
biological response. 
The purpose of this experimental study was to determine the 
effects of the anti-insulin receptor antibody in vivo and to attempt 
to develop a model of the Type B syndrome of insulin resistance by 
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"passive transfer" of these antibodies from a patient’s serum to the 
rat. The rat was selected because the effects of Anti-R Ab on the rat 
adipocyte have been well studied and because of the animal's small 
plasma volume. The parameter chosen for evaluation was plasma glucose 
level, because of the well documented effect of Anti-R Ab on glucose 
transport and metabolism, and the comparative ease of determination of 
this parameter. Relatively "pure" and concentrated immunoglobulin, 
depleted of anti-insulin antibodies, was obtained by processing the 
patient's serum through a four step protocol: ammonium sulfate 
precipitation, insulin-Sepharose affinity column, protein A-Sepharose 
affinity column, and concentration through u11rafi11ration . 
The indication for this study is clear. The effect of isolated 
Anti-R Ab in vivo has never been demonstrated. It is not clear 
whether the acute stimulatory effects of the antibody seen in vitro 
are significant at the level of the whole, intact organism with its 
multitude of compensatory mechanisms. Further, it is unclear whether 
the desensitization phenomenon is applicable only in the 3T3-L1 fatty 
fibroblast, or whether it has broader implications. 
There are three major precedents for this type of study. Toyka 
et a 1 (174) developed an animal model of myasthenia gravis, a disorder 
characterized by autoimmunity to the acetylcholine receptor, by the 
passive transfer of patients' serum to mice. The passive transfer of 
thyroid-stimulating antibodies from patients with Graves' disease 
(175) produces a delayed and prolonged elevation of thyroxine in the 
blood in rodents (the long-acting thyroid stimulator, LATS effect). 
Finally, Armin and co-workers at Guy's Hospital in 1960 (176) were 
able to induce "experimental diabetes" in rats through the 
intraperitonea 1 and intravenous injection of anti-insulin antibodies. 
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II) METHODS 
The present study was divided into four seperate sections. In 
the first of these sections, plasma obtained from patient B-10 (177), 
afflicted with the Type B syndrome, and plasma from a pooled control 
source were processed through a four step protocol to extract and 
purify the IgG fraction. The second section of the study consisted of 
assays designed to characterize the efficacy of each of the four steps 
in the purification protocol. In the third section of the study, the 
in vitro characteristics of the final anibody preparations were 
determined. The last section of the study consisted of the in vivo 
experimental trials of the final antibody preparations. An overview 
of the experimental design is depicted in Figure 2. 
A) Purification of the Anti-Insulin Receptor Antibody 
Two hundred milliliters of frozen plasma from pooled from normal 
controls and two hundred milliliters of frozen plasma obtained during 
therapeutic plasmapheresis of patient B-10 were processed through a 
four step protocol consisting of: 1) ammonium sulfate precipitation, 
2) insulin-Sepharose 4B affinity column, 3) protein A-Sepharose IgG 
affinity column, and 4) concentration through u11rafi11ration . All 
steps were carried out at four degrees Centigrade to retard bacterial 
growth. 
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Figure 2 
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Ammonium sulfate precipitation was utilized to provide a 
selective concentration of the immunoglobulin fraction of the plasma 
flow rates and samples. This procedure was necessary to 
minimize overloading and clogging of the affinity columns in the 
subsequent two steps. In order to further guard against overloading 
the affinity columns, the 'raw immunoglobulin fraction' from the 
ammonium sulfate precipitation was split into six equal fractions 
before application to the insulin-Sepharose 4B affinity column. Each 
of these six fractions was, in turn, applied to and recycled over the 
insulin-Sepharose 4B affinity column. The intent of this step was to 
remove anti-insulin antibodies known to be present in patient B-10's 
plasma. The portion of each of the six 'raw immunoglobulin fractions' 
which did not bind to the column - the insulin-Sepharose 4B 
"flow-through" - was then applied to the protein A-Sepharose column 
to isolate the IgG component of these fractions. The eluates of the 
protein A-Sepharose column were neutralized, with respect to pH, and 
subsequently pooled into a single sample. In the final step of the 
protocol, these samples were concentrated using an Amicon 
u1trafi1tration device. These preparations were the final 
anti-insulin receptor antibody (Final Anti-R Ab) and final control 
antibody (Final C Ab) used in the subsequent components of the study. 
1) Ammonium Sulfate Precipitation 
The initial 200 ml plasma sample was diluted with an equal volume 
of cold phosphate buffered saline (pH 7.4). A saturated ammonium 
sulfate solution (pH 7.5) was added dropwise to the four hundred ml 
sample, with continuous stirring, at 4' C until a final ammonium 
sulfate concentration of 33% was obtained (178). The dropwise 
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addition occurred over the course of approximately two hours and the 
solution was allowed to stand overnight to complete the precipitation. 
The ammonium sulfate solution and precipitant were then 
centrifuged at 5000 x g for thirty minutes and the supernatant was 
discarded. The pellet was resuspended with 33% ammonium sulfate 
solution to the original volume and then recentrifuged as above. The 
pellet was then resuspended to the original volume with phosphate 
buffered saline (PBS) and dialyzed exhaustively against PBS to obtain 
the 'raw immunoglobulin fraction'. This 'raw immunoglobulin fraction' 
was made up to a volume of 200 milliliters. A two ml aliquot was 
saved for assay and the remainder was split into six equal fractions 
of 33 ml each. 
2) Insulin-Sepharose 4B Affinity Column 
An affinity column for anti-insulin antibodies was prepared by 
coupling porcine insulin (Iletin, Eli Lilly, Chicago) to CN-Br 
activated Sepharose 4B (Pharmacia, Piscataway, NJ) according to the 
general protocol of the manufacturer. Three grams of CN-Br activated 
Sepharose 4B was allowed to swell for fifteen minutes in 1 mM HC1 and 
was washed on a sintered glass filter with 1 mM HC1. The gel was then 
washed with coupling buffer solution (0.1 M sodium bicarbonate 
solution at pH 8.3 containing 0.5 M NaCl). An insulin solution was 
mixed with coupling buffer solution to obtain 10 mg of insulin in 15 
ml of solution (optical density @ 280 nm = 0.438). This solution 
allowed for the recommended 5 ml of solution per gram of dry Sepharose 
gel, and also allowed for 1 mg of insulin per 1 ml of final gel 
volume, which is one-tenth the manufacurer's recommendations, in order 
to minimize steric hindrance and maximize flow rates. The gel was 
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incubated in the insulin-coupling buffer solution for two and one-half 
hours, while shaking, at 37' C. This was then spun down, and the 
supernatant discarded (optical density @ 280 nm = 0.030). Over ninety 
percent of the insulin was bound to the Sepharose 4B beads. The 
insulin-Sepharose 4B was then titrated to pH 8.2 and allowed to remain 
overnight at room temperature to hydrolyze residual, unoccupied 
coupling groups on the Sepharose beads. The slurry was then 
repeatedly washed, alternating 100 ml of eluting buffer (3.0 M 
guanidine-HCl at pH 3.0) and 100 ml of PBS (pH 7.4). The 
insulin-Sepharose slurry (15 ml) was then suspended in a Pharmacia 
column (approximately 1 cm diameter x 15 cm) and stored at 4' C. A 
sample of the column "flow-through" was saved for radioimmunoassay. 
One of the six 'raw immunoglobulin' fractions was applied to the 
insulin-Sepharose 4B affinity column and recycled over the column an 
additional three times. The column was then washed with 100 ml PBS 
and this sample - insulin-Sepharose 4B "flow-though" - was collected 
(volume of 135 ml). A two ml aliquot was saved for subsequent assay. 
Fifty ml of eluting buffer was then passed over the column and 
fractions were collected. The peak protein fractions (optical density 
@ 280 nm) were pooled and dialyzed exhaustively against PBS. A two ml 
aliquot of the eluant was saved for subsequent assay. In turn, each 
of the six 'raw immunoglobulin' fractions was processed through the 
insulin-Sepharose 4B affinity column. 
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3) Protein A-Sepharose IgG Affinity Column 
The protein A-Sepharose affinity column was used to isolate the 
IgG from the anti-insulin antibody depleted 'raw immunoglobulin' 
fraction (179). 
Three grams of protein A-Sepharose powder (Pharmacia, Uppsala, 
Sweden) was allowed to swell for fifteen minutes in 200 ml of 0.1 M 
phosphate buffer (pH 7.4). The gel was then washed with phosphate 
buffer on a sintered glass filter three times. The slurry (10 ml) was 
then poured into a Pharmacia column (approximately 1 cm diameter x 15 
cm) and stored at 4' C. According to the manufacturer's 
specifications, this column had 20 mg of bound protein A, with a 
binding capacity of 200 mg of IgG. 
The insu1in-Sepharose 4B affinity column "flow-through" was 
applied to the protein A-Sepharose column and recycled over the column 
an additional two times. The column was then extensively washed with 
a minimum of 300 ml PBS (30 x column volume). The column was then 
eluted with 50 ml of 0.58% acetic acid in 0.15 M NaCl. Fractions 
(2.25 ml) were collected and those with peak protein concentration 
were pooled (optical density @ 280 nm). The pH was immediately 
adjusted by dialysis against PBS (pH 7.4). All six insulin-Sepharose 
4B affinity column "flow-through" samples were processed in an 
identical manner, the pH adjusted, and the six samples were pooled. 
Bovine serum albumin (BSA) was added to a final concentration of 0.1% 
(w:v) and the pH was adjusted by dialysis against PBS. BSA was added 
as an inactive protein to minimize non-specific adsorption of the 
immunoglobulin preparation. A two ml aliquot of both the control and 
patient B-10 "protein A eluant" fractions was saved for subsequent 
assay. 
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4) Concentration Through U1trafi1tration 
The samples obtained after elution from the protein A-sepharose 
column were placed in an Amicon u1trafi1tration device (Amicon Corp., 
Lexington, Mass) equipped with a PM-10 u1trafi1tration membrane 
(exclusion MW 10,000 daltons). This membrane size was selected to 
allow for free filtration of any insulin contaminant, while retaining 
IgG and BSA. The concentration was performed with a pressure of 50 
psi, supplied by nitrogen gas, and constant stirring. The sample from 
patient B-10 was concentrated from an initial volume of 80 ml to a 
volume of 15 milliliters. This was the final anti-insulin receptor 
antibody preparation (Final Anti-R Ab). The control sample was 
concentrated from an initial volume of 57 ml to a volume of 8 
milliliters. This sample, the final control antibody preparation, was 
designated 'Final C Ab'. A two ml aliquot of each was saved for 
subsequent assay. These preparations were used in the in vitro and in 
vivo experiments. 
B) Anti-Insulin Receptor Antibody Isolation Assays 
The second major section of the experimental study involved the 
use of three assays to analyze the effectiveness of the antibody 
isolation protocol described above. A f1uorescamine protein assay 
(180) was used to determine the protein concentration of each of the 
steps of the protocol. The second assay system measured the ability 
of each sample to inhibit I<125>-labeled insulin binding to IM-9 
cultured human lymphocytes (181), an established cell culture line at 
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NIH with a large number of cell surface insulin receptors. This assay 
was used to quantitate the amount of anti-insulin receptor antibody 
present in each sample. The third assay was used as a qualitative 
screen for the presence of anti-insulin antibodies. 
1) Fluorescamine Protein Assay 
The sample, ranging in volume from 5 to 50 microliters, was 
pipetted into a glass test tube. Seven hundred microliters of borate 
buffer (0.125 M borate buffer - pH 8.4) was then added, followed by 
the addition of one hundred microliters of "fluram" solution (300 mg 
fluorescamine in 100 ml acetone). The solution was then vortexed for 
fifteen seconds and allowed to stand for fifteen minutes. Fluoresence 
was measured with a fluorimeter with excitation wavelength of 390 nm 
and emission wavelength of 475 nm. Protein content was determined by 
comparison with a standard linear relationship established with 
appropriate dilutions of bovine serum albumin. 
2) IM-9 Cultured Human Lymphocyte Binding Inhibition Assay 
Cells from an established cultured human lymphocyte line, IM-9, 
were grown to confluence. The cells were centrifuged at 400 x g for 
five minutes and resuspended to one-tenth the original volume in HEPES 
lymphocyte buffer with 0.1% BSA. The cells were counted and 
resuspended in fresh buffer to a concentration of five million cells 
per milliliter. Fifty microliters of test sample (actual sample or 
appropriate dilution prepared with normal control serum) was pipetted 
into a plastic test tube. Four hundred and fifty microliters of IM-9 
cell suspension was then added to each of the tubes, and the tubes 
were allowed to incubate for two hours at room temperature. The cells 

were then centrifuged and washed. The cell pellet was resuspended in 
500 microliters of HEPES lymphocyte buffer solution containing 
I<125>-labeled insulin and allowed to incubate for two hours, with 
agitation, at 15’ C. The cells were then resuspended and duplicate 
100 microliter aliquots were added to respective 400 microliter 
plastic microfuge tubes containing 200 microliters of HEPES buffer. 
All microfuge tubes were kept on ice. The tubes were microfuged for 
45 seconds, the supernatant aspirated , and the tips of the tubes 
(containing the cell pellet and associated I< 1 25>-insu1in) were 
counted. 
3) Anti-Insulin Antibody Screen 
The underlying principle in this assay is that the inorganic 
substance talc will bind free insulin (44). The assay measures the 
ability of a test sample to inhibit this binding due to the presence 
of anti-insulin antibodies. 
In each assay tube, a 200 microliter test sample was added to 100 
microliters of I<125>-labeled insulin and 700 microliters of a veronal 
buffer. This mixture was allowed to incubate overnight at room 
temperature. One 50 mg talc tablet was added to each assay tube and 
vortexed. The tube was allowed to stand for ten minutes, vortexed 
again, and let stand for five additional minutes. The tube was then 
centrifuged at 1500 x g for ten minutes. The supernatant, containing 
insulin bound by anti-insulin antibody, was aspirated and collected. 
Both the supernatant and the talc pellet, containing previously 'free' 
insulin, were counted in a gamma counter for ten minutes. 
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C) In Vitro Characterization of B-10 Anti-Insulin Receptor Antibody 
In the third section of the study, the in vitro characteristics 
of the B-10 Anti-R Ab preparation were determined. The focal point of 
this characterization was the analysis of the relative effectiveness 
of the Anti-R Ab to produce an insulinomimetic effect versus its 
ability to inhibit insulin binding to the insulin receptor. The 
insulinomimetic capacity was characterized through the use of an assay 
which measured the ability of the Anti-R Ab to stimulate oxidation of 
C<14>-1abe11ed glucose in rat adipocytes (157). The binding 
inhibition assay also used rat adipocytes so that a direct comparison 
in the same cell type could be made (157). 
1) Isolation of the Rat Adipocytes 
Two male rats (100-180 grams) with free access to rat chow and 
water, were sacrificed and the epididymal fat pads removed. The fat 
pads were minced into several small pieces and digested by placing 
them in a solution containing 6 mg of collagenase in 3 ml of 
Krebs-Ringer bicarbonate buffer A (KRB A: NaCl 0.118 M, KC1 0.005 M, 
calcium chloride 0.0013 M, magnesium sulfate 0.0012 M, sodium 
bicarbonate 0.025 M, and 2% (w:v) bovine serum albumin, all gassed 
with 95% oxygen - 5% carbon dioxide, and adjusted to pH 7.5 with 1 N 
NaOH). The digestion took place over one hour in a shaking water bath 
at 37' C. The adipocytes were then isolated by filtration through a 
silk screen. The cells were washed three times with KRB-A and then 
resuspended in either 10 ml of KRB-A for the glucose oxidation assay, 
or 5 ml of KRB-A for the binding inhibition assay. 
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2) Rat Adipocyte Glucose Oxidation Assay 
Glucose oxidation was assessed by measuring the conversion of 
C<14>-g1ucose to C<14>-carbon dioxide. Rat adipocytes were isolated as 
above using 100-120 gram rats. In to each polyethylene incubation 
flask, 100 microliters of sample, 100 microliters of the adipocyte 
cell suspension, and 800 microliters of incubation medium were added. 
Incubation medium consisted of KRB-A with 0.3 mM glucose and 10 
microcuries of C<14>-glucose (New England Nuclear). These incubation 
vessels were gassed with 95% oxygen - 5% carbon dioxide and incubated 
in a shaking water bath at 37' C for one hour. At the end of the 
incubation period, the solution was acidified with 0.3 ml of 2 N 
sulfuric acid and the evolved C<14>-carbon dioxide gas collected in 
hanging wells, which were then counted in glass scintillation bottles 
containg 15 ml of scintillation fluid. The assay was done in 
triplicate. An insulin standard curve was constructed using 
appropriate dilutions of insulin, and the maximal insulin-induced 
stimulation of glucose oxidation determined. The stimulation achieved 
by the 'Final Anti-R Ab' was then compared to the maximal stimulation 
achieved by insulin. 
3) Rat Adipocyte Binding Inhibition Assay 
Rat adipocytes were prepared as outlined above using four 150-180 
gram rats. One hundred microliters of sample was incubated with 400 
microliters of adipocyte cell suspension at 30' C for 15 minutes. The 
cells were then washed three times in KRB-A (to minimize any serum 
effects on binding not related to immunoglobulin). The cells were 
resuspended to a volume of 450 microliters and incubated with 50 
microliters of I<125>-insu1in (0.2 ng/ml with 100 microcuries per 
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microgram). The incubation tubes were placed in a shaking water bath 
at 37' C for 20 minutes. Two hundred microliters of this cell 
suspension was then pipetted into each of two four hundred microliter 
polyethylene microfuge tubes containing 100 microliters of dinonyl 
phthalate. These tubes were microfuged for one minute, and the fat 
pellet was isolated and counted in the gamma counter. The assay was 
done in quadruplicate. Non-specific binding was considered the amount 
of I<125>-insu1in bound in the presence of 100 micrograms/ml unlabeled 
insulin. 
D) B-10 Anti-Insulin Receptor Antibody In Vivo Experimental Trials 
In the final part of the experimental study, a series of six 
female rats, weighing about 200 grams, received 1.5 ml intraperitoneal 
injections of one or two of the following: Final Anti-R Ab, Final C 
Ab, regular crystalline insulin, or normal saline. Prior to the 
injections, all animals had been fasted overnight. Blood samples were 
taken periodically thereafter and plasma glucose levels were 
determined. In order to facilitate repeated blood sampling, and 
minimize stress and artifact arising from the sampling procedure 
itself, all blood samples were obtained through a previously placed 
venous cannula in unrestrained, unanesthetized animals. 
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Chronic Venous Sampling in the Unrestrained Rat 
The cannula used was made of Silastic Medical Grade Tubing (0.020 
in I.D. x 0.037 in O.D. - Dow Corning, Midland, MI). The catheter, 
with a 45' beveled tip, was held in place through a sleeve system 
placed 25 mm from the cannula tip (see Figure 3). The sleeve was 
constructed of a 7 mm section of silastic tubing (0.040 in I.D. x 
0.085 in O.D. - Dow Corning), secured to the cannula by three 
overriding 1-2 mm bands of this same size tubing. The bands supplied 
a compression fit of the sleeve onto the underlying cannula. 
The cannula was placed in a manner similar to that described by 
Popp and Brennan (182). Briefly, the rat was anesthetized with sodium 
pentobarbital. The animal was shaved on the anterior and posterior 
neck and thorax and prepped. A midline incision was made at the 
suprasternal notch and extended 2-3 cm cephalad. The right external 
jugular vein was easily identified as it passed from beneath the 
clavicle and was dissected free. Three loops of 5-0 silk were passed 
beneath the vein. The cephalad suture was tied, ligating the vessel, 
and a small venotomy was made between the cephalad and middle sutures. 
The cannula was introduced through the right external jugular vein 
into the right atrial sinus, and the caudad suture was secured around 
the vessel and cannula, taking care to insure patency of the cannula. 
The cannula was flushed with heparinized saline (100 units/ml) from a 
1 ml syringe. With patency assured, the middle suture was then tied 
around the vessel and between the caudad and middle silastic bands of 
the sleeve system. The cephalad suture, already tied and ligating the 
vessel, was tied a second time around the cannula sleeve between the 
cephalad and middle silastic bands of the sleeve system. A 1.5 cm 
incision was then made between the scapulae. Then, a 13-gauge trocar 
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was used to tunnel the catheter subcutaneously over the animal's left 
shoulder to the dorsal incision. The ventral incision was closed 
using stainless steel clips (Auto-Clips, Clay Adams, Parsippany, NJ). 
The catheter was then passed through a protective stainless steel 
spring (approximately 10" long) connected to an anchoring flange which 
was sutured to the suprascapular fascia. The skin over the flange was 
closed with stainless steel clips. The catheter and spring were then 
attached in a coaxial fashion to a sterile brass swivel assembly 
(model 375/22, Instech labs, Philadelphia, PA), which was permanently 
connected to the top of a modified metabolic cage (see Figure 4). The 
animal was allowed at least two full days for recovery, during which 
time cannula patency was maintained by periodic flushing with small 
amounts of heparinized saline (100 units/ml). 
Plasma Glucose Level Determination 
Blood samples (0.2 ml) were obtained using a syringe and 23 gauge 
scalp vein infusion set with a blunted needle to withdraw through the 
venous cannula. Care was taken to assure that an adequate blood 
sample, free of heparinized saline, was obtained. Blood samples were 
transferred to lithium heparin microfuge tubes and the catheter 
flushed with heparinized saline. Blood samples were immediately 
centrifuged for 90 seconds in a Beckman microfuge. The plasma 
fractions were withdrawn and transferred to fresh lithium heparin 
tubes and placed on ice. Glucose determinations (183) were done in 
duplicate using a glucose analyzer (Beckman Instruments, Fullerton, 
CA) . 
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In Vivo Experimental Trials 
All animals were allowed free access to water but were fasted 
overnight (13 + /- 1 hour). After the overnight fast, three or more 
baseline blood levels were obtained. The animals were then briefly 
anesthetized using carbon dioxide gas and were given 1.5 ml 
intraperitonea1 injections (normal saline, Final Anti-R Ab, or Final C 
Ab). Blood samples were taken through the venous cannula at thirty 
minutes, one hour, two hours, three hours, and periodically 
thereafter. 
Both of the animals (rat #1 & #5) receiving intraperitonea1 
saline injections were allowed free access to food after blood samples 
had been taken at six and eight hours, respectively. One of the 
animals, rat #4, receiving an injection of Final C Ab was allowed free 
access to food after a blood sample was taken at twelve hours. These 
three animals were then fed ad libidum overnight and throughout the 
next day. The three animals were then fasted overnight, as above, and 
a second intraperitoneal injection, this time of Final Anti-R Ab, was 
administered. The other three animals (rats #2, #3, and #6) received 
only single intraperitoneal injections. Blood samples were monitored 
as above. 
Regular crystalline insulin was given in a similar fashion by 
intraperitoneal injection in doses of 50, 100, and 350 ng/kg. Blood 
samples were obtained and glucose levels determined as described 
above. 
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figure 3 - Placement of Intravenous Cannula and Sleeve System 
in the Anesthetized Rat 
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Figure 4 - Apparatus for Chronic Venous Sampling 
Using Modified Metabolic Cage 
(after Burt et al (185)) 
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RESULTS 
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III) RESULTS 
A) Effectiveness of Antibody Purification Protocol 
The first objective of this study was to extract and purify the 
IgG fraction of the plasma obtained in therapeutic plasmapheresis of 
patient B-10, and the IgG fraction of the sample of control plasma. 
The second portion of the study consisted of a series of three assays 
performed to quantitate the efficiency of each of the procedures used 
in the purification protocol. 
The results of the fluorescamine protein assay are tabulated in 
Table V and the results of the cultured human lymphocte (IM-9) binding 
inhibition assay, corrected for non-specific binding, are recorded in 
Table VI. Table VII contains data derived from Table VI. The total 
amount of anti-insulin receptor "activity" was calculated by 
multiplying the titer of the aliquot used in the binding inhibition 
assay by the total volume of the sample at each step in the 
purification protocol. Recovery of this "activity" is calculated for 
each step and cumulative recovery is also recorded. The purification 
data recorded in Table VIII were derived from Table V and Table VII. 
The anti-insulin receptor "activity" per milligram of protein was 
calculated for each step in the protocol and recorded in Table VIII. 
The purification obtained by each step of the protocol is also 
recorded in Table VIII. Table IX contains the results of the screen 
for anti-insulin antibodies. All tables and figures cited in this 
section are at the end of the results section. 
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1) Ammonium Sulfate Precipitation 
The 33% ammonium sulfate solution precipitated 4.4% of the total 
protein present in patient B-10's plasma and 3.3% of the total protein 
in the control plasma. The recovery of anti-insulin receptor activity 
after ammonium sulfate precipitation was 30%, while the purification 
obtained was approximately seven-fold. In taking into consideration 
the f1uorescamine assay results of subsequent steps, it can be seen 
that the ammonium sulfate precipitation is highly selective in the 
protein that it does precipiptate. Approximately thirty to forty 
percent of the protein precipitated was IgG. This can be safely 
stated because of the selectivity of the protein A column for binding 
IgG insures that the preponderance of the total protein present in the 
final sample was immunoglobolin G. The results indicate that while 
ammonium sulfate was effective in its ability to precipitate 
immunoglobulins selectively over other plasma proteins, it was 
successful in precipitating only about one-third of the functional 
activity of the Anti-R Ab present in the original, whole plasma 
sample . 
2) Insulin-Sepharose 4B Affinity Column 
The important data in interpreting the efficacy of the 
insulin-Sepharose 4B column are contained in Table IX, which shows the 
results of the screen for anti-insulin antibodies (Anti-I Ab). In 
interpreting this data, it is important to recognize that the 
supernatant contains radioactive1y-1 abe 1ed insulin bound to Anti-I Ab , 
whereas the talc pellet contains labeled insulin that was "free" in 
solution, and the ratio of bound/free is a useful guide in assessing 
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the relative amount of Anti-I Ab activity present in each sample. The 
results show that in each instance the eluant of the insulin affinity 
column contained a substantial amount of anti-I activity, and a 
greater amount of anti-I activity than the "flow-through". The 
post-protein A-Sepharose B-10 sample contained roughly comparable 
(slightly less) anti-I activity as a 1:2 dilution of a sample of 
initial B-10 plasma. This same post-protein A sample contained a 
twelve-fold increase in anti-insulin receptor activity, relative to 
undiluted B-10 plasma. However, the 'Final Anti-R Ab' preparation did 
contain anti-insulin antibodies, indicating that the column was not 
completely effective in depleting Anti-I Ab. 
Only 2.2% of the total protein in the 'raw immunoglobulin 
fractions' of patient B-10's plasma was lost by retention on the 
insulin affinity column, while 5.0% of the total protein in the 
control sample was lost (Table V). The recovery and purification data 
(Table VIII) indicate that a loss of approximately 20% of the 
anti-insulin receptor activity present in the 'raw immunoglobulin' 
fraction occurred. This is in contrast to the loss of only 2.2% of 
total protein . 
The sample saved after the insulin-Sepharose 4B column had been 
washed and suspended in a column was sent for radioimmunoasssay by an 
independent lab (Meloy Laboratories, Springfield, VA). 
Radioimmunoassay indicated that the column was "leaking” insulin at a 
rate of 327 picograms per milliliter. 
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3) Protein A-Sepharose IgG Affinity Column 
As noted in the METHODS section, the six separate fractions of 
B-10 plasma and control plasma, which had been passed separately over 
the insulin-Sepharose and protein A-Sepharose columns, were pooled 
into single post-protein A control and B-10 samples. 
The recovery data show the remarkable ability of the protein 
A-Sepharose column to bind IgG. Virtually all (94%) of the 
anti-insulin receptor activity applied to the column was bound. The 
results of the protein assay also show that 31% of the protein in the 
control sample applied to the column was retained, compared to 42% of 
the protein in the B-10 sample. These results are corrected for the 
addition of 0.1% BSA. 
4) Concentration Through U1trafi1tration 
The 80 ml of B-10 post-protein A sample was concentrated 5.4 fold 
to a final volume of 15 ml. The 57 ml of control post-protein A 
sample was concentrated 7.1 fold to a final volumne of 8 ml. The 
protein content data in Table V are corrected assuming concentration 
of the carrier protein BSA. 
The data in Table V reveal that while only 9% of the protein 
present in the B-10 post-protein A sample was lost in the process of 
concentrating the sample, approximately 42% of the protein contained 
in the control post-protein A sample was lost during concentration. 
The recovery data (Table VII) show that approximately 25% of the 
anti-R activity present in the B-10 post-protein A sample was lost 
during the concentration process. This loss is not explained by 
simple protein loss, which amounted to only 9% of the total protein 
present. 
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In order to be certain that there was not a significant amount of 
insulin present in the 'Final Anti-R Ab', a sample was applied to a 
Sephadex G-50 column, equilibrated with 0.05 M ammonium carbonate (pH 
8.0) and eluted with the same buffer. At this point, about 7 ng/ml of 
free insulin per ml of concentrated IgG applied to the column was 
detected. 
Separate analysis using an immunodiffusion assay (184) showed 
that less than one percent of the immunoglobulin was IgM or IgA. 
B) B-10 Anti-Insulin Receptor Antibody 'In Vitro* Characterization 
The third component of the experimental study characterized the 
in vitro activity of the final anti-R preparation. The ability of 
this preparation to inhibit the binding of I<125>-insulin to rat 
adipocytes was analyzed and recorded in Table X. The assay shows a 
dose-dependent ability of the 'Final ^nti-R Ab' preparation to inhibit 
insulin binding. The ability of the Anti-R Ab to produce an 
insulin-like effect was determined by measuring its ability to 
stimulate the oxidation of C<14>-glucose to C<14>-carbon dioxide. The 
results are recorded in Table XI. This assay shows a similar 
dose-dependent ability of the Anti-R Ab preparation to stimulate 
glucose oxidation. The results of these two assays show that at each 
concentration, the 'Final Anti-R' preparation stimulated glucose 
oxidation to a greater extent than it inhibited insulin binding. The 
results are presented graphically in Figure 5. 
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C) B-10 Anti-Insulin Receptor Antibody 'In Vivo1 Trials 
An important finding to be noted at the outset in the in vivo 
experiments, is the ability of the fasted animal to maintain a normal 
baseline plasma glucose level for a period of up to 36 hours. Of 
equal importance is the observation that the injections of the control 
antibody preparation had no discernable effect on plasma glucose 
levels. In the four animals that were given intraperitoneal 
injections of the ’Final C Ab' preparation (animals #2, #3, #4, #6 - 
Figures 6 & 8) and in the two animals given saline injections (animals 
#1 & #5 - Figures 7 & 9), there was not a single instance in which the 
animals’ blood glucose level fell below 65 mg/dl (n=53). In only one 
instance (animal #2), prior to the administration of a sample, did the 
blood glucose fall slightly below 70 mg/dl. Also of note is that in 
very few instances did the blood glucose level exceed llOmg/dl. When 
this level was exceeded, it was usually immediately following the 
stress of carbon dioxide inhalation anesthesia and intraperitoneal 
injection. 
In contrast to the animals' demonstrated ability to maintain 
stable plasma glucose levels following control antibody injection, 
when the final anti-insulin receptor preparation was administered 
(Figures 7, 8, 9) there was a severe and prolonged drop in plasma 
glucose levels. The fall in plasma glucose took between one and three 
hours to occur. While the drop in plasma glucose leveled off after 
1-3 hours, it required 8-12 hours to reach a peak effect. In two 
cases (animals #1 & #4), the hypoglycemia was of sufficent magnitude 
to cause loss of consciousness, and in the other animal receiving 
'Final Anti-R Ab', plasma glucose fell to 25 mg/dl (animal #5) twelve 
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hours after injection. This severe hypoglycemic state persisted as 
long as the animal was fasted and glucose levels were monitored (up to 
twenty-four hours post-injection ) . Twenty-four hours after the 
injection of Anti-R Ab (plasma glucose level at 22 mg/dl), animal #1 
was fed ad libidum for two days (spot plasma glucose level 140 
mg/dl) and then fasted overnight. The following morning, three days 
after receiving the Anti-R Ab injection, the animal's plasma glucose 
level had dropped to 50 mg/dl in the fasted state. 
The effect of administering porcine insulin intraperitoneally is 
shown in Figure 10. Insulin at a dose of 50 ng/kg of body weight was 
found to have no discernable effect on plasma glucose levels of the 
fasted rat. When given at 100 ng/kg of body weight, plasma glucose 
rapidly fell to 40% of baseline level, but quickly rebounded to above 
baseline within four hours. Insulin given at 350 ng/kg caused loss of 
consciousness within two hours (data not shown). It is important to 
note the rapidity of onset of the effect of insulin. 
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Table V - Fluorescamine protein Assay 
PROTEIN VOLUME TOTAL PROTEIN 
(MG/BL) 
(±S■D,) 
(ML) (mg) 
PATIENT B-10 PLASMA 
A. Initial Plasma 41 ± 1.4 200 8200 
B. 'Raw Immunoglobulin' 1.8 ± 0.06 135 360 
C. Insulin-Sepharose #1 0.51 ± 0.04 135 69 
Affinity Column #2 0.54 ± 0.03 130 70 
"Flow-through" #3 0.51 ± 0.01 140 71 
#4 0.39 ± 0.01 135 53 
#5 0.36 ± 0.01 135 49 
#6 0.32 ± 0.01 125 40 
Total 352 
D. Post-Protein A Column 1.8 ± 0.0 82 148 
E. 'Final Anti-R Ab' Prep 9.0 ± 0.6 15 135 
CONTROL PLASMA 
A. Initial Plasma 58 + 1.4 200 1160 
B. 'Raw Immunoglobulin 1 2.2 + 0.11 200 440 
C. Insulin-Sepharose #1 0.55 + 0.01 135 74 
Affinity Column #2 0.50 + 0.03 160 80 
"Flow-through" #3 0.64 + 0.06 150 96 
#4 0.51 ± 0.01 145 74 
#5 0.40 + 0.01 130 52 
#6 0.37 + 0.03 135 42 
Total 418 
D. Post-Protein A Column 2.2 + 0.1 59 130 
E. 'Final C Ab' Prep 9.3 + 0.1 8 75 

Table VI - Lymphocyte Binding Inhibition Assay 
PATIENT B-10 PLASMA TI TER* 
A. Initial Plasma 1:330 
B. 'Raw Immunoglobulin' Fraction 1:100 
C. Insulin-Sepharose Affinity Column 
"FIow-through" #1 1:30 
#2 1:25 
#3 1:20 
#4 1:15 
#5 1:13 
#6 1:11 
D. Post-Protein A Column 1:175 
E. 'Final Anti-R Ab' Prep 1:700 
* - Dilution causing 50% inhibition of I[125]-insulin bind 
to IM-9 culture human lymphocytes 
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Table VII - Anti-Insulin Receptor Antibody Recovery 
TITER* VOLUME 
(ML) 
'ANTI-R' 
ACTIVITY 
(*) 
RECOVERY 
FROM 
PREVIOUS 
STEP 
CUMULATIVE 
RECOVERY 
PATIENT E-10 PLASMA 
A. Initial Plasma 1:330 200 132,000 - - 
B. 'Raw Immunoglobulin1 1:100 200 40,000 30% 30% 
C. Insulin-Sepharose #1 1:30 135 8,100 
Affinity Column #2 1:25 130 6,500 
"Flow-through" #3 1:20 140 5,600 
#4 1:15 135 4,100 
#5 1:13 135 3,500 
#6 1:11 125 2,800 
Total 30,600 77% 23% 
D. Post-Protein A Column 1:175 82 28,700 94% 22% 
E. 'Final Anti-R Ab' Prep 1:700 15 21,000 73% 16% 
* - See Table VI 
(*) - In arbitrary units; calculation corrected for i ml. assay volume 
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Table VIII - Anti-Insulin Receptor Antibody Purification 
'anti-r' P U R I F I 
ACTIVITY 
PER MG FROM 
TITER* PROTEIN PROTEIN PREVIOUS 
(MG) (*) STEP 
CATION 
CUMULATIVE 
PATIENT B-10 PLASMA 
A. Initial Plasma 1:330 20.5 16 - - 
B. 'Raw Immunoglobulin' 1:100 0.9 110 7-fold 7-fold 
C. Insulin-Sepharose #1 1:30 0.25 120 
Affinity Column #2 1:25 0.27 93 
"Flow-through" #3 1:20 0.25 80 
#4 1:15 0.20 75 
#5 1:13 0.18 72 
#6 1:11 0.16 69 
Total Activity 30,600 350 88 (-20%) 6-fold 
D. Post-Protein A 
Column 1:175 0.9 190 2.2-fold 12-fold 
E. 'Final Anti-R Ab' 1:700 4.5 160 (-20%) 10-fold 
* - See Table VI 
(*) - See Table VII 
Note - D & E corrected for addition of 0.1% BSA 
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Table IX - Anti-Insulin Antibody Screen 
SUPERNATANT TALC BOUND/ 
(CPM*) (CPM*) FREE 
PATIENT B-10 PLASMA 
A. Initial Plasma 
(1:2 dilution) 1446 7677 0.188 
B. Initial Plasma 
(1:20 dilution) 804 8521 0.084 
C. Insulin-Sepharose 
Affinity Column 
#1 "Flow-through" 742 8571 0.087 
El uate 1000 8274 0.121 
#2 "Flow-through" 750 8480 0.088 
Eluate 1108 8372 0.132 
#3 "Flow-through" 680 8723 0.078 
Eluate ** 
#4 "Flow-through" 648 8803 0.074 
Eluate ** 1028 8272 0.124 
#5 "Flow-through" 661 8810 0.075 
El uate 821 8603 0.095 
#6 "Flow-through" 688 8599 0.080 
Eluate 900 8674 0.104 
D. Post-Protein A Column 1421 8016 0.177 
E. 'Final Anti-R Ab1 Prep 2308 7223 0.320 
CONTROL PLASMA 
A. Initial Plasma 606 8468 0.072 
B. 'Final C Ab' Prep 576 8784 0.066 
POSITIVE CONTROL 
Control Serum 5743 2288 2.51 
* - counts per minute 
* * - samples pooled through technical error 
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Table X - Adipocyte Binding Inhibition Assay 
NAL ANTI-P Ab' 
PREPARATION 
(DILUTION) 
% TOTAL 
RADIOACTIVITY 
BOUND 
(± S.D,) 
NON-SPECIFIC 
BINDING 
<7 SPECIFIC % 
BINDING 
(± S.D.) 
CONTROL 
BINDING 
(± S.D.) 
% BINDING 
INHIBITION 
(± S.D.) 
Control 2.33 0.31 2.02 
1: 3000 2.80 + 0.06 0.32 2 .48 + 0.06 12 2.8 
1:1000 2.84 + 0.21 0.31 2 .53 ± 0.21 125.2 
1: 300 2.21 + 0.10 0.32 1 .89 ± 0. 16 93.6 + 5.0 6.4 + 5.0 
1:100 1.46 + 0.06 0.29 1 . 17 + 0.06 57.9±3.0 42.1+3.0 
1: 30 0.71 + 0.03 0.30 0 .41 ± 0.03 20.3+1.5 79.7+1.5 
1: 10 0.46 + 0.04 0.31 0 .15 ± 0.04 7 .4 + 2.0 92.6 + 2.0 
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Table XI - Adipocyte Glucose Oxidation Assay 
'Final Anti-R Ab' 
PREPARATION 
(DILUTION) 
Glucose 
Oxidation 
(CPM±S.D, ) 
% Maximal Insulin 
Stimulation* 
1:30,000 271 ± 8 3.5 ± 0.9 
1:10,000 363 ± 68 13.7 ± 7.5 
1:3,000 728 ± 86 54.4 ± 9.6 
1:1,000 867 ± 15 69.9 ± 1.7 
1:300 1005 ± 38 85.3 ± 4.2 
1:100 1172 ±110 103.9 ±12.2 
1:30 1220 ±109 109.3 ±12.2 
* - calculated as follows: 
% maximal insulin stimulation = sample - basal activity / 
maximal insulin stimulation - basal activity 
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ANTI-RECEPTOR ANTIBODY (Dilution) 
Figure 5 - In. Vitro Characterization of Anti-Insulin Receptor 
Antibody - Comparison of Binding Inhibitory 
AND INSULINOMIMET IC EFFECTS 
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TIME (hours) 
Figure 7 - Effect of Anti-Insulin Receptor Antibody, 
('Final Anti-R Ab' Preparation), and Saline 
on Plasma Glucose Concentration in Rat #1. 
(* - ANIMAL GIVEN I.V. DEXTROSE AND SMALL 
AMOUNT OF FOOD ) 

'/> 94 
Figure 8 - Effect of Anti-Insulin Receptor Antibody, 
('Final Anti-R Ab' Preparation), and 
Control Antibody, ('Final C Ab' Preparation), 
on Plasma Glucose Concentration in Rat #4, 
(* - ANIMAL GIVEN I.V. DEXTROSE AMD FED ) 
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Figure 9 - Effect of Anti-Insulin Receptor Antibody, 
('Final Anti-R Ab' Preparation), and Saline 
on Plasma Glucose Concentration in Rat #5. 

FA
ST
IN
G
 
PL
A
SM
A
 
G
LU
C
O
SE
 
(%
) 
9 6 
« * > « « i -- 
-|5 0 2 4 6 8 10 22 24 
TIME OF FAST FROM INJECTION (hr) 
- Figure 10 - Effect of Anti-Insulin Receptor Antibody (q), 
50 ng/kg Insulin (o), and 100 ng/kg Insulin (o), 
on the Plasma Glucose Concentration of the 
Fasted Rat, 

97 
DISCUSSION 

98 
IV) DISCUSSION 
A) Anti-Insulin Receptor Antibody Purification 
The results obtained by assaying samples collected during the 
purification of the anti-insulin receptor antibody yielded several 
significant pieces of information. First, a marked loss of antibody 
was incurred during ammonium sulfate precipitation despite meticulous 
attention paid to maximizing yield and purification during this step. 
Dropwise addition of an ammonium sulfate solution was performed to 
minimize local concentration differences and non-specific 
precipitation. The data shows that only 30% of the anti-insulin 
receptor activity was recovered after this step. This is in marked 
contrast to the findings of Flier et a 1 (20), in which serum from a 
different patient was used. Using a similar procedure, they were able 
to obtain selective prcipitation with a recovery of 95% of IgG present 
in the initial plasma. The only difference in the methods employed 
was that Flier did not allow for overnight precipitation. Although 
ammonium sulfate is reported to cause only minor protein denaturation 
(178), the overnight incubation with the longer exposure to high salt 
concentrations may account for the relatively poor yield. 
The insulin-Sepharose 4B affinity column was effective in 
depleting the patient’s plasma of anti-insulin antibodies. As noted, 
the protein A-Sepharose eluate contained a twelve-fold enhancement of 
anti-insulin receptor activity, relative to initial B-10 plasma, while 
the amount of anti-insulin activity was comparable to a 1:2 dilution 
of control plasma. The column, however, also caused a relatively 
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large amount of non-specific binding (retention of 5% of total protein 
present in the control 'raw immunoglobulin' fractions). The reasons 
for this are unclear, since care was taken in the preparation of the 
column to minimize factors which might promote clogging and 
non-specific interactions. Another difficulty is that the use of the 
column caused a 20% loss of anti-insulin receptor activity. This is 
in marked contrast to the loss of only two percent of total protein. 
It is possible that the relatively 'harsh' elution conditions (3.0 M 
guanidine-HCl @ pH 3.0) were responsible for causing denaturation of 
anti-insulin receptor activity. The amount of leakage of the 
insulin-Sepharose column is insignificant, considering that in the 
next step of the purification protocol, the protein A column was 
'washed' with a minimum of 300 ml PBS (thirty times the bed volume). 
The remarkable effectiveness of the protein A-Sepharose column, 
with retention of 94% of anti-insulin receptor activity, is in 
accordance with the findings of Ey et a 1 (186). According to the 
manufacturer's specifications (Pharmacia), the protein A column had an 
IgG binding capacity of 200 milligrams. The fluorescamine assay 
indicated that none of the six insulin-Sepharose 4B "flow-through" 
fractions contained more than 100 mg of total protein. In addition, 
the preparations were recycled over the column twice. These factors 
undoubtedly contributed to the effectiveness of the protein A column. 
The use of ultrafiltration caused a substantial loss of control 
protein (42%), while only 9% of B-10 protein was lost. It is not 
clear how this loss occurred, since identical Amicon u1trafi1tration 
membranes were used in each case. It is highly improbable that the 
control sample contained a larger amount of smaller proteins that were 
subject to filtration (M.W. less than 10,000). It is possible that a 
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technical error occurred during the concentration of the sample, 
although the source of this error is not readily identifiable. 
Nonetheless, the ’Final C Ab’ still qualifies as an adequate control 
in this study. The use of u1trafi1tration also caused a loss of 
one-quarter of the anti-receptor activity. This is perplexing, in 
view of the loss of less than ten percent of total protein. Again, 
the possibility of denaturation must be entertained. The six-fold 
concentration may have triggered precipitation and/or denaturation. 
The determination that the free insulin concentration was 
approximately 7 ng/ml was initially of concern. However, it is 
apparent that this contaminant was not of significance in vivo . 
In conclusion, the purification protocol was an effective process 
for isolating anti-insulin antibody depleted immunoglobulin (IgG) from 
patient B-10's plasma. 
B) In Vitro Characterization of Anti-Insulin Receptor Antibody 
As depicted in Figure 5, the anti-insulin receptor antibody was 
able to stimulate glucose oxidation at a much lower concentration than 
that at which it was able to inhibit binding. The data show that the 
concentration difference is approximately one hundred-fold. As Taylor 
et al (146) point out, this shift in the dose-response curve for 
binding inhibition versus bioeffect is comparable to the effect of 
insulin itself. They point out that it requires approximately one 
hundred times the ambient insulin concentration to inhibit 
I-<125>-insu1in as it does to stimulate a bioeffect in rat adipocytes. 
This phenomenon is probably related to the presence of "spare" 
receptors on the cell surface. 
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C) In Vivo Experimental Trials of Anti-Insulin Receptor Antibody 
The major finding of this study was that the passive transfer of 
immunoglobulin G from the plasma of a patient afflicted with the Type 
B syndrome produces a marked insulinomimetic effect in vivo in rats. 
This effect is directly analogous to the acute effect of anti-insulin 
receptor antibody that has been demonstrated repeatedly in vitro . 
This is the first time this effect of anti-insulin receptor antibody 
has been demonstrated in vivo . 
Effect is Distinct from Insulin's Effect 
The effect of the ’Final Anti-R Ab' preparation was clearly not 
due to an insulin contaminant. The concentration of insulin in the 
'Final Anti-R Ab' was demonstrated to be approximately 7 ng/ml. This 
corresponds to a dose of less than 60 ng/kg in the animals used in 
this study. While an insulin dose of 100 ng/kg produced a substantial 
effect in these animals, four findings indicate that the observed 
effect was not due to insulin: 1) lack of response to control 
preparation; 2) magnitude of effect; 3) time of onset of effect 
following administration; and 4) duration of effect. 
The lack of response to the control preparations, 'Final C Ab', 
is reassuring. The 'Final C Ab' was processed through the exact same 
isolation protocol as the 'Final Anti-R Ab' preparation. There was 
not a single instance, following administration of 'Final C Ab', that 
the animals' plasma glucose concentration fell below 70 mg/dl. This 
suggests that the observed effect cannot be induced by control plasma 
and, further, that it was not the result of contamination during the 
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purification protocol. The stability of plasma glucose levels 
(greater than 70 mg/dl but less than 110 mg/dl) attests to the ability 
of the animal to maintain stable blood glucose levels and the ability 
of the venous sampling system to allow blood samples to be taken 
without introducing agitation and stress as a confounding variable on 
plasma glucose level determination. 
The magnitude of the drop in plasma glucose following the 
injection of the antibody cannot be accounted for by the insulin 
concentration present in the 'Final Anti-R Ab'. The concentration of 
insulin administered with the 'Final Anti-R Ab' did not exceed 60 
ng/kg of body weight. In these animals, a dose of 50 ng/kg had no 
detectable effect on blood glucose and a dose of 100 ng/kg caused a 
fall in plasma glucose to 40 mg/dl. In contrast, following 
administration of the Anti-R Ab, plasma glucose levels fell to less 
than 20 mg/dl, a much more severe hypogy1ycemic state. 
The onset of action of intraperitoneal insulin is also much 
faster than that observed with the antibody. Insulin's action occurs 
rapidly within one hour, and the effect reaches its maximum within two 
hours. In distinction, the effect of the antibody requires a longer 
period of onset and requires longer to reach its peak of action. This 
is probably a consequence of the longer period required for the 
absorption and distribution of the larger immunoglobulin molecule. As 
reported by Coons (187), serum levels of intravascu1ar1y administered, 
radioactively-labeled , globulins fall acutely by approximately fifty 
percent, usually within six to eight hours, corresponding to 
equilibration with the extravascular space. This equilibration time 
would account for the eight to twelve hours required before a maximal 
effect is observed with 'Final Anti-R Ab'. 
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Finally, the obvious distinction between the animals response to 
insulin and the response to anti-insulin receptor antibody is the 
length of duration of the effect. Whereas insulin's action lasted 
less than four hours before plasma glucose returned to basal levels, 
the effect of the Anti-R Ab was still very pronounced after 
twenty-four hours. The persistence of this effect could be the result 
of the greater affinity of the antibody for the insulin receptor, and 
thereby, the longer time required for the antibody to dissociate from 
the receptor. Anti-receptor antibody dissociates from the receptor 
with a half-time of 10-12 hours, whereas insulin dissociates with a 
half-time of fifteen minutes (158). Further, when animal #1 was fed 
ad libidum for two days, and then fasted overnight, the blood glucose 
was 50 mg/dl (samples repeated). Therefore, the effect persisted for 
at least 72 hours in this one experiment. Extrapolating from the 
analysis of Dixon et a 1 (188), it can be determined that the half-life 
of intravascularly administered, radioactively labeled, immunoglobulin 
in the unsensitized rat is three to four days. Therefore, after 72 
hours, the observation that the plasma glucose was depressed to 50 
mg/dl is readily accounted for by postulating a persistent, yet 
diminished effect due to clearance of the antibody. 
Mechanism of Anti-R Induced Hypoglycemia 
The finding of hypoglycemia in the fasted rat following passive 
transfer of anti-insulin receptor antibody are unequivocal. The most 
straightforward mechanism accounting for this is a direct agonistic 
effect of the anti-receptor antibody on the insulin receptor, 
analogous to the in vitro findings. The persistent question that 
remains, however, is why is an insulinomimetic effect produced by 
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antibodies which induce severe insulin resistance in most patients ? 
It is possible that there is some subtle difference in the 
insulin receptor between humans and rats that causes a different type 
of interaction between the human antibody and the rodent insulin 
receptor. Rat insulin differs from human insulin by, at most, four 
amino acids (189), and only one of these (residue #4 of the A chain) 
is in the bioactive site proposed by Ginsberg (31). This suggests 
that the receptor binding site has also been similarly conserved in 
evolution. Evidence suggests that the insulin receptor has been more 
highly conserved than the insulin molecule itself (190), and that the 
rat and human receptors are indeed very similar (157). However, these 
findings do not rule out the possibility that a slight antigenic 
difference is responsible for the differences in effect. The one 
finding that makes this hypothesis untenable is that the anti-insulin 
receptor antibody will also produce insulinomimetic effects in human 
adipose tissue in vitro (147,153). 
It is possible that the hyperglycemic, insulin-resistant state 
was not reproduced because of an insufficient concentration of 
antibody. As judged by the cultured human lymphocyte (IM-9) binding 
study (Table VI), the titer of the anti-receptor antibody in the 
'Final Anti-R Ab' preparation was 1:700. Utilizing Dixon's findings 
(188), who showed that intravenously administered immunoglobulin 
concentrations drop by fifty percent during redistribution, and 
assuming that intravascular volume accounts for five percent of body 
weight, it is logical to suppose that the immunoglobulin redistributes 
within a space equivalent to ten percent of body weight. This 
corresponds to a ten-fold dilution of antibody. If, on the other 
hand, one assumes homogeneous distribution throughout the 
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extracellular fluid volume, equivalent to twenty percent of body 
weight, this is a twenty-fold dilution. These two methods of 
analysis indicate that, due to dilutional factors, the equilibrated 
titer of antibody in the animal is somewhere between 1:35 and 1:70. 
This contrasts with the titer of patient B-10's plasma of 1:330. 
Another possibility is that the time of exposure to the antibody 
was not sufficient to induce a "desensitized" insulin resistant state. 
Marshall et a1 (76), examining insulin receptor recycling and 
down-regulation, suggest that alterations take longer to occur in 
vivo . They contrasted down-regulation in simple medium as opposed to 
complete medium and found that down-regulation did not occur to a 
significant extent in cells in the complete medium. Although a direct 
analogy to desensitization, insulin resistance, and the passive 
transfer of anti-receptor antibody cannot be made, the underlying 
principle may be applicable. This could be responsible for the 
failure to observe desensitization after twenty-four hours in vivo , 
whereas the same phenomenon occurs in six to eight hours in vitro . 
Subsequent studies in our laboratory have demonstrated that the 
inability, in the studies reported herein, to induce a hyperglycemic, 
insulin-resistant state by passive transfer could have been due to 
time and concentration considerations. Repeated administration of 
anti-receptor antibody was demonstrated to induce a persistent 
hyperglycemic (200-400 mg/dl) state in fed rats (191), believed to be 
similar to the Type B syndrome. It is thought that the repeated 
administration of immunoglobulin was necessary to maintain an adequate 
concentration and duration of exposure to induce "desensitization" , 
analogous to that demonstrated by Karlsson e t a 1 (158) and Grunfeld e t 
a1 (164) in in vitro studies. 
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In this context, it is of note that Toyka et a 1 , in their 
efforts to develop a model of myasthenia gravis in mice, found that 
prolonged exposure to antibody levels comparable to those which 
existed in myasthenic patients was necessary to induce a 
myasthenic-like state (174). 
Previous studies in vitro have shown that anti-insulin receptor 
antibody can mimic the bioactivity of insulin on target tissues, 
inhibit binding of insulin to its receptor, and desensitize tissue to 
insulin (152). The current study demonstrates that the 
insulinomimetic effect also occurs in vivo , and from subsequent 
studies (191), it has been inferred that desensitization also occurs 
in vivo . In most patients, the binding inhibitory and desensitizing 
effects predominate, leading to severe insulin resistance (152). 
However, hypoglycemia also occurs in these patients (152), suggesting 
that the insulinomimetic effect can also predominate (152). 
The mechanism determining the relative contribution of these 
factors is unknown. It is interesting to speculate that it may be 
related to the "mediator" and "anti-mediator" effects described by 
Larner et a1 (121). It has been demonstrated that biphasic responses 
to insulin do occur. Seals and Czech (129) have shown that incubation 
of adipocyte membranes with increasing concentrations of insulin or 
for increasing periods of time can lead to a biphasic production of 
"mediator". Cheng et a 1 (123) have demonstrated convincingly in one 
system that biphasic responses are due to production of "mediator" and 
"ant-mediator" molecules. However, it has never been demonstrated 
that these "mediator" molecules mimic insulin's membrane actions, and 
therefore it is highly speculative to infer that they may influence 
glucose transport. 
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Further investigation of the mechanism that determines the 
relative expression of the insu1inomimetic and desensitizing effects 
of the anti-insulin receptor antibody will not only have impact on the 
clinical approach to Type B patients, but will undoubtedly have 
ramifications upon our understanding of the broader considerations of 
insulin action, insulin resistance, and diabetes mellitus. 
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